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Abstract
Microglia are the resident immune cells of the Central Nervous System
(CNS). Beside classic inflammatory activities shared with macrophages,
microglia actively participate in activity-dependent plasticity and learn-
ing processes [1] [2], as sculpting the neuronal circuitry during devel-
opment [3] [4]. Microglia have been shown to be key players in the
pathogenesis and progression of many neurodegenerative disorders and
they are responsible for brain homeostasis and monitor the brain en-
vironment with their ever-moving processes [5] [6]. However, their
role, either promoting or preventing pathology, is debated. On one
hand, excessive activation of microglia leads to oxidative stress, neu-
roinflammation, and eventually neuronal death [7]. On the other hand,
microglial activation might be harnessed to carry out protective activ-
ities in the brain, such as phagocytosis of aggregates, synaptic pruning
and formation, and the maintenance of healthy neuronal circuits [8].
Therefore, it is important to identify and modulate selectively the neu-
roprotective activities of microglia. The idea of microglia cells as the
natural scavengers of the brain becomes especially interesting when
dealing with diseases with the loss of proteostasis such as Alzheimer’s
disease.
In the search of neuroprotective agents against neurodegeneration,
neurotrophins have been historically considered as potential therapeu-
tic candidates but usually with actions targeted to natural neuronal
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population. In this thesis I tested the hypothesis that microglia rep-
resent a new target cell for Nerve Growth Factor (NGF) in the brain.
So far sparse experiments in the literature suggest this insight.
In the literature microglia cells are known to be a source of neu-
rotrophins [9] [10][11], most notably the Brain Derived Neurotrophic
Factor (BDNF) which has been shown to promote synapse formation
[1] and NGF [12] [13]. However, the extent of the modulation NGF
might exert on physiological microglial functions and how this effect
might come into play in neurodegenerative disorders has not been in-
vestigated yet.
Indeed, the main cellular targets of the neurotrophin Nerve Growth
Factor (NGF) [14] in the central nervous system are considered to be
the cholinergic neurons of the basal forebrain (BFCNs) [15], while its
sources are mainly cortical and hippocampal neurons [16].
Consistently, interference with NGF signaling (trkA-NGF signalling)
in the adult brain leads to deficits of the cholinergic system that has
been related to the mechanisms driving neurodegeneration, as in the
AD11 transgenic mouse model [17] [18]. The expression of anti-NGF
antibodies selectively neutralizing mature NGF in the adult brain de-
termines a progressive comprehensive neurodegeneration with neuroin-
flammation as the earliest observed change, at a presymptomatic phase
[19] [20]. A similar progressive neurodegeneration is observed in trans-
genic mice expressing a neutralizing anti TrkA antibody in the adult
brain [21]. Changes in NGF homeostasis in the brain, with particular
regard to the ratio of NGF to proNGF levels, have also been linked to
Alzheimer’s disease [22].
However the overall neurodegenerative picture induced by anti-
NGF or anti-TrkA antibodies in those transgenic models is much
broader than what one would expect on the basis of an action of the
antibodies on the BFCNs exclusively. Moreover, the loss of NGF-TrkA
signaling in the CNS, obtained by conditionally deleting NGF or TrkA
genes in CNS cells derived from nestin-positive cells, has proven not to
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be sufficient in inducing severe cognitive impairments or neurodegen-
eration in mice [23]. Altogether, this body of results has motivated our
search for non neuronal targets of NGF in the adult brain. Microglia
was a strong candidate, because (1) previous work had suggested that
NGF could modulate some aspects of microglial cells in culture [12]
and (2) transcriptomic studies in the AD11 mouse model expressing
anti-NGF had shown that neuroinflammation is the earliest pheno-
typic alteration, already at a presymptomatic phase (1 month of age;
[19] [20]).
In this thesis I show that microglia cells are true target of NGF
both in vivo and in vitro and that the activity carried out by this
neurotrophin on these myeloid cells might result neuroprotective in
the context of Alzheimer’s Disease.
Chapter 1
Introduction
Microglia constitute around 10% of the total cells in the adult CNS
[24]. Microglia are distributed throughout the CNS and vary in density
in both rodents and humans, with subtle variations in morphology in
different cytoarchitectural regions [25]. The word glia was coined in
the mid 19th century and defined as the nerve glue. For decades, it
was assumed to be a uniform matrix, until cell theorists raised the
neuron doctrine which stipulated that nervous tissue was composed of
individual cells. The term astrocytes was introduced in the late 19th
century as a synonym for glial cells and later Santiago Ramon y Cajal
defined a third element distinct from astrocytes and neurons.
Pio del Rio-Hortega, an alumnus of the Cajal School, introduced
the modern terms and the concept of microglia that we use today.
Microglia was defined cellular element of the central nervous system
in a book chapter called Microglia[26] of the book Cytology and Cel-
lular Pathology of the Nervous System edited by Wilder Penfield in
1932. He thoroughly described both oligodendrocytes and microglia
to clearly distinguish them from astrocytes. Rio-Hortega described
microglia postulating the following visionary concepts: 1) microglia
enter into the brain during early development 2) these invading cells
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have amoeboid morphology and are of mesodermal origin. 3) They use
vessels and white matter tracts as guiding structures for migration and
enter all brain regions. 4) They transform into a branched, ramified
morphological phenotype in the more mature brain (known today as
the resting microglia). 5) In the mature brain, they are found almost
evenly dispersed throughout the central nervous system and display
little variation. 6) Each cell seems to occupy a defined territory. 7)
After a pathological event, these cells undergo a transformation. 8)
Transformed cells acquire amoeboid morphology similar to the one
observed early in development. 9) These cells have the capacity to
migrate, proliferate and phagocytose [27] [28].
Microglia cells are often described as the macrophages of the cen-
tral nervous system but a series of recent findings in the mouse has
established that microglia are a unique cell population distinct from
macrophages. Fate mapping has revealed that adult microglia are de-
rived from precursors that leave the yolk sac on E8.5 E9.0, entering
the neural tube via the primitive bloodstream [29] [30] as in figure 1.1.
As the progenitor cells journey to the CNS, they gain lineage-
specific gene expression and ultimately differentiate into mature mi-
croglia. The yolk-sac-derived microglia remain throughout life, with
the population being maintained by self-renewal in the healthy CNS
with little contribution from bone-marrow macrophages [31] [24]. Mi-
croglia are not macrophages that migrate into the brain but instead
they are known to represent a distinct population of resident tissue
mesenchymal cells that populate the CNS during early development
[32] [33]. Remarkably, since the origins and responses of microglia and
macrophages are different, the roles they play in mitigating or propa-
gating pathology could be different as well. Microglial are derived from
primitive erythromyeloid progenitors in the yolk sac, distinct from the
definitive hematopoiesis from which the majority of macrophages is
derived.
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Figure 1.1: Microglia have a distinct lineage and molecular signa-
ture (A) The genesis and progression of yolk-sac-derived cell lineages
are illustrated. Microglial are derived from primitive erythromyeloid
progenitors in the yolk sac (embryonic hematopoiesis, indicated in yel-
low), distinct from the definitive hematopoiesis (shown in green) from
which the majority of macrophages are derived. Figure from Salter
and Beggs 2014 [24].
1 Microglia Cell Physiology
Thus, microglia cells are distinct from macrophages. In the brain,
microglia, as macrophages in the other body regions, are the primary
immune effector and they are key players in brain injury and disease.
However, their role in the intact postnatal brain has remained elusive
for a long time. Resting microglia are extremely dynamic in vivo,
perpetually changing their morphology by extending and retracting
highly motile processes on a time scale of minutes [34] [5]. This unex-
pected finding led to a series of discoveries suggesting potential roles
of microglia in postnatal development, adult neuronal plasticity, and
circuit function. In the next chapters some of these physiological mi-
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croglial activities and their implications for normal brain function will
be described. In particular the focus will be on microglia morphology
and motility, the activation state (inflammation and the engulfing abil-
ity by microglia) and the interaction between microglia and neurons.
Then how microglia physiology changes in pathological conditions will
be discussed.
In Figure 1.2 from the paper The Role of Microglia in the Healthy
Brain by Marie-Eve Tremblay et al [35], three different microglial func-
tions are represented:(1) the continuous scanning of their local envi-
ronment by highly motile microglial processes, (2) the structural and
functional interactions with synaptic elements through direct contacts
and exchanges of molecular signals, and (3) the contribution to re-
structuring the neuronal circuits by phagocytosing synaptic elements
and newborn cells.
Figure 1.2: Overview of microglial behavior in the healthy brain. (1)
Motility, (2) Synaptic interaction (3) Phagocytosis. In green are shown
dendritic branch and spines, while in blue are shown cellular inclusions.
1.1 Morphology and Motility
In 1996 Georg W. Kreutzberg published the Review Microglia: a sen-
sor for pathological events in the CNS [36]. Here the microglial rapid
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activation in response to minor pathological changes in CNS was de-
scribed for the first time. This ability to respond quickly to a variety
of signalling represents a state of vigilance to changes in their extra-
cellular space. In response to any kind of brain damage or injury,
microglial cells become activated and undergo morphological as well
as functional transformations. In the healthy brain, microglia are
characterized by cellular processes branching off from the small soma
with further distal arborisation. This morphological state is typical of
ramified microglia, called also resting microglia, the latter definition
implying an intimate link between morphology and function [28]. The
idea that microglia assume various morphological appearances corre-
lated with distinct functional states arose through studies conducted
in the facial nerve system [37]. It was demonstrated that depending on
whether facial motoneurons regenerate after a reversible injury (facial
nerve axotomy) or degenerate after irreversible injury (ricin intoxica-
tion), microglia cells will respond in characteristic fashion. In figure
1.3 the original illustration from article [38] explains the new concept
of functional plasticity of microglia.
Injured or diseased neurons cause resting microglia to become ac-
tivated by emitting injury signals, as ATP [38] [34]. Microglia state of
activation changes with the severity of neuronal damage. The mildest
injuries cause hyper-ramification of microglia [39], that represents an
intermediate stage between the resting and the reactive form. In the
hyper-ramification state microglia start to become hypertrophic. This
morphology correspond to the state of activation in vivo. Many types
of neuronal damage shift resting microglia to a reactive phenotype.
Nolte et al, in their paper published in 1996, investigated the regula-
tion of microglia motility induced by different inflammatory mediators
using time-lapse video microscopy. In this paper it was demonstrated
how microglia cells exhibit a high resting motility characterized by
intense ruffling of cell membranes followed by lamellipodia extension
within few seconds. It was shown that this process is accompanied by
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Figure 1.3: Different states of activation of microglia from Streit et al
1999.
a rapid rearrangement or the actin cytoskeleton. Later, Stence and
colleagues studied microglia dynamics in rat brain tissue slices using
stacks of confocal optical sections taken at intervals of 2-5 min for
several hours [40]. During this time microglia became activated and
shifted from a ramified phenotype to amoeboid macrophages. Ram-
ified microglia progress to amoeboid macrophages through a stereo-
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typical sequence of three steps, as described in figure 1.4.
Figure 1.4: Multistep model of microglial activation dynamics from
Stence Glia 2001 [40].
First, in the withdrawal stage, the existing ramified branches of
activating microglia do not actively extend or engulf other cells, but
instead retract back (mean rate, 0.5-1.5 µm/min) and are completely
readsorbed into the cell body. Second, in the motility stage, a new set
of dynamic protrusions, which can exhibit cycles of rapid extension and
retraction (both up to 4 µm/min), abruptly emerges. Sometimes new
processes begin to emerge even before the old branches are completely
withdrawn. Third, in the locomotory stage, microglia begin translo-
cating within the tissue (up to 118 µm/h). The translocation starts
only after the new protrusions emerge. From these experiments, it
was concluded that the rapid conversion of resting ramified microglia
to active amoeboid macrophages is accomplished not by converting
quiescent branches to dynamic ones, but rather by replacing existing
branches with an entirely new set of highly motile protrusions.
This suggests that the ramified branches of resting microglia are
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normally incapable of rapid morphological dynamics necessary for the
function of activated microglial. More generally, these observations
identified changes in the dynamic behavior of activating microglia and
thereby helped definining distinct temporal and functional stages of
activation [40].
As described above resident microglial cells in the healthy brain
are thought to rest in a dormant state, whereas activation is associ-
ated with structural changes, such as motile branches or migration
of somata [40] [41] [38]. Most tissue preparations represent trau-
matic injuries but, using time-lapse two-photon imaging of microglia,
it has been demonstrated that the fine terminal of microglial processes
are highly dynamic not only during the activation but also in their
presumed resting state, continually surveying their microenvironment
with extremely motile processes and protrusions in the intact mouse
cortex [34] [5] as shown in figure 2.12.
Upon traumatic brain injury, for example when blood-brain barrier
disruption occurs [5] or after ATP injection [34], microglial processes
rapidly and autonomously change as described above on the site of
injury without cell body movement, creating a barrier between the
healthy and injured tissue. Thus microglia can be defined as busy
and vigilant housekeepers in the adult brain [34]. In vivo two-photon
microscopy revealed that microglial processes and arborizations are
highly mobile [34] [5]. This microglia ability to monitor the envi-
ronment probably depends on purinergic stimulation and involve a
support from astrocytes [34] [42].
In vitro microglia cells usually do not show the ramified struc-
ture characteristic of the tissue microglia. Microglia show ameboid
cell morphology, no polarity, many short processes that they extend
into lamellipodia to even round cells. Some cells show morphological
reorganization after LPS administration [43]. Moreover, ameboid mi-
croglial cells progressively ramify when co-cultured with astrocytes.
Thus, microglia undergo morphological transformations from ramified
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Figure 1.5: Microglial cells are highly dynamic in the resting state in
vivo. (A) Maximum-intensity projections of an individual microglial
cell (45 to 75 mm below the pia) at the beginning (left) and 1 hour
after (center) the start of a transcranial time-lapse recording. (Right)
Overlay showing extensive formation (green) and deletion (red) of mi-
croglial processes. (B) Extensions (green) and retractions (red) of
processes over the time course of 20 min. (C) Length changes of the
processes shown in (B) as a function of time. (Right) Mean motility
values in mm/min for extensions and retractions. (D) Branch motil-
ity occurred at every branch order. (E) Example images of microglial
protrusions (arrowheads) from a time-lapse recording. (F) Length
changes over time of the two protrusions P1 and P2 indicated in (E).
Vertical dashed lines mark the acquisition times of the images shown
in (E). Arrows indicate protrusion lifetime. (G) Lifetime histogram of
protrusions [5].
to bipolar to tripolar and ameboid states in accordance with local en-
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vironmental cues associated with astrocytes in subconfluent cultures
[44].
It was through these studies on morphological changes that a mi-
croglial role in the diseased CNS was recognized. The theory of mi-
croglia as sensors of pathologic changes was formulated in 1996 by
Kreutzberg [36].
Given the importance of microglia morphology for its physiologi-
cal role, it is important to study the changes in microglia morphology,
but it is not clear from the literature how activated microglia might
be accurately described. Recently, two articles, that describe an anal-
ysis of microglia morphology in vivo were published. In the CNS,
microglia are the only cells that express CX3CR1, also known as the
fractalkine receptor [45], so Dan R. Littman and colleagues developed
in 2000 a knock-in mouse model CX3CR1-GFP/+ to study the role
of fractalkine [46], but later the same model was used to study mi-
croglia morphology. Franck Verdonk and colleagues developed a 3D
automated confocal tissue imaging system coupled with morphological
modelling of many thousands of microglial cells. This study revealed
a precise and quantitative assessment of major microglia cell features:
cell density, cell body area, cytoplasm area and number of primary,
secondary and tertiary processes. The use of two morphological cri-
teria, the complexity index (CI) and the covered environment area
(CEA), allowed to establish an innovative approach lying in (i) an
accurate and objective study of morphological changes in healthy or
pathological conditions, (ii) an in situ mapping of microglial distri-
bution in different neuroanatomical regions and (iii) a study of the
clustering of numerous cells, allowing us to discriminate different sub-
populations. Using clustering analysis, the authors highlighted that,
at resting state, microglial cells are distributed in four microglial sub-
populations defined by their CI and CEA with a regional pattern and
a specific behaviour. These results suggest that microglial cells are
distributed in different defined sub-populations that present specific
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behaviour after pathological challenge, allowing to postulate for a cel-
lular and functional specialization [47]
More recently, Maŕıa del Mar Fernández-Arjona and colleagues de-
scribed a new method to classify microglia by their morphology, using
images obtained by section scanning individual microglial cells from
various regions (septofimbrial nucleus, hippocampus and hypothala-
mus) at different times (2, 4 and 12 h) post-injection of a single dose
of the enzyme neuraminidase (NA) within the lateral ventricle (LV).
Each cell yielded a set of 15 morphological parameters. This method
allowed classifying microglia population in four clusters. A linear dis-
criminant analysis (LDA) suggested three specific parameters to objec-
tively classify any microglia by a decision tree. In addition, a principal
component
analysis (PCA) revealed two extra valuable variables that allowed
to further classifying microglia in a total of eight sub-clusters or types.
The spatio-temporal distribution of these different morphotypes in a
rat inflammation model allowed to correlate them to microglial acti-
vation status and brain location [48].
1.2 Resting (monitoring) state
It is probably reductive to apply the term resting to the non-activated
microglia since they are continually involved in surveillance with their
processes, which are largely responsible for this function, and therefore
continually motile. The cell body of resting microglia is not motile,
there is minimal expression of cell surface markers and release of cy-
tokines and chemokines, and the cells are not involved in phagocytosis.
However, as they clearly are not at rest, microglia under these circum-
stances might be better described as monitoring microglia [49]. It is
probably accurate to state that the function of resting microglia is
largely unknown although key roles in homeostasis, host defense and
repair have been attributed to these cells [50]. It has been hypothe-
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sized that microglia are responsible for dealing with the microdamage
that occurs commonly in the brain and that this ranges from forms
of plasticity which are associated with resculpting (perhaps eliminat-
ing) synapses to responders to capillary damages [51]. As the ma-
jor resident immunocompetent cells in the brain [52] [53], microglia
are responsible for sampling the microenvironment and play a role
in removing cell debris [50]. This surveying role is likely to be an
important factor in maintenance of homeostasis; microglia possess an
array of ion channels, and expression and activation of potassium chan-
nels, in particular have been suggested to be important in production
of inflammatory mediators in response to stressors [54] and neuronal
survival/death [55]. Similarly, at least in certain circumstances, mi-
croglia, like astrocytes, express the glutamate uptake protein, GLT-1,
suggesting that they may play a role in protection against glutamate
toxicity [56]. The role for microglia in repair has been associated with
their ability to produce neurotrophic factors, although it is also unclear
whether release of neurotrophins can be achieved by resting cells [57].
What is clear is that microglia are exquisitely sensitive to stressors and
rapidly change their morphology and function in response to all forms
of insult. Microglia can be stimulated and may then express partic-
ular cell surface markers which promote chemotaxis or infiltration of
circulating cells into the CNS which permit interaction of microglia
with other cells. They may be alternately non-phagocytic cells pro-
ducing soluble proinflammatory molecules or they may be phagocytic
and motile [36] [58]. Intermediate states may also exist: for exam-
ple, it has been proposed that expression of major histocompatibility
complexes (MHC) enables phagocytic function and that engulfment of
pathogens or cell debris promotes release of soluble proinflammatory
molecules [59] shown in figure 1.6.
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Figure 1.6: At least five functional states of microglia exist but in-
termediate states, and states which are multifunctional, probably also
exist.
1.3 Activation state
As cited previously, microglia in healthy brain have a ramified mor-
phology, with a small resting soma with fine cellular processes that
scan and monitor the environment. Microglial activation is the tran-
sition from resting cells to an activated state that occurs upon dis-
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turbance of tissue homeostasis. This transition should be considered
a change in functional phenotype. Cells shift from the surveillance
mode (one type of activity) to a reactive profile, withstanding with
altered homeostasis. The adjustments occur rapidly, in minutes or
also seconds: cells change their chemotactic reorientations through
non-transcriptional modifications. Significant transcriptional modifi-
cations take place within a few hours [51].
Infection, trauma, ischemia, neurodegenerative diseases, or altered
neuronal activity, ie. any disturbance or loss of brain homeostasis
indicating real or potential danger to the CNS, can evoke rapid and
profound changes in the microglial cell shape, gene expression and
functional behavior which summarily is defined as microglial activa-
tion [28] Phenotypically, the complexity of the cellular processes is
reduced, and microglia revert to an amoeboid appearance. Microglia
can become motile and actively move to a lesion or herd of infec-
tious invaders following chemotactic gradients. Local densities of mi-
croglia can also increase by proliferation, to provide more cells for
the defense against invading germs and to organize for the protection
and restoration of tissue homeostasis. Induction and rearrangement
of surface molecules to support cell-cell and cell-matrix interactions,
changes in intracellular enzymes as well as release of multiple factors
and compounds with proinflammatory and immuno-regulatory effects
are additional elements of the activation process. Microglia can un-
fold their phagocytotic activities to clear tissue debris, damaged cells,
or microbes. The release of chemoattractive factors by microglia re-
cruits and guides immune cell populations to the CNS. Presentation
of antigens by microglia to T cells can subsequently aid the adaptive
immunity in fight against viral or bacterial invasion. The range of
microglial activities also covers the production of neurotrophic factors
and the physical association with endangered neurons.
Various kinds of stimulators have been predicted for microglia ac-
tivation: some kinds of molecular and cellular mechanisms are shown
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in figure 1.7.
Figure 1.7: Putative molecules for microglial activation and activated
microglia-derived cytotoxic and neurotrophic molecules. Figure from
”Microglia: Activation and Their Significance in the Central Nervous
System” Nakajima et al 2001 [60].
One category is represented by non-material stimulators, the elec-
trical potential change resulting from neuronal injury and changes in
the ion medium around injured neurons are candidates. The other cat-
egory is that of biologically active substances, which may include low
molecular weight molecules such as peptides and hormones. Growth
factors or cytokines may also be able to activate microglia. Among
the cytokines are macrophage colony-stimulating factors (M)-CSF and
granulocyte-macrophage colony-stimulating factors (GM)-CSF [61].
As for other activators, calcitonin gene-related peptide(CGRP) and
ATP [62] induce immediate early gene mRNA expression and transla-
tion in microglia. Likewise, ATP can cause biological responses such
CHAPTER 1. INTRODUCTION 22
as chemotaxis [63], release of plasminogen (PGn) and interleukin IL-
1β, and activation of nuclear factor (NF) KB in cultured microglia
[64]. Therefore, it is likely that some molecules derived from neurons
and/or astrocytes trigger the activation of microglia in vivo as shown
in figure 1.7.
Microglial activation can be accompanied by proliferation. The
factor(s) necessary for mitogenesis in microglia were clarified by an
in vitro study. Microglia can proliferate in response to GM-CSF, M-
CSF, and multi-CSF (IL-3) [65]. Moreover, CSFs, IL-2, IL-4, IL-5,
and tumor necrosis factor (TNF)α are reported to induce proliferative
activity in cultured microglia. In vivo, CSF or CSF-like factors may
be responsible for the proliferation and activation of microglia.
As described above, many molecules and conditions can trigger a
transformation of resting (or surveying) microglia to activated (alerted
or reactive) states. These have in common that they indicate a threat
to the structural and functional integrity of the CNS. Microglial cells
are prepared to recognize a wide range of signs for homeostatic surveil-
lance, independent of their biochemical nature (peptides, lipoproteins,
glycolipids, nucleotides) or diverse (patho)physiological implications.
The list is shown in figure 1.8
The activation of microglia may have serious consequences on neu-
ronal and astroglial activity and survival. The effects of activated
microglia on neuronal survival is debated. On one hand, activated mi-
croglia in culture have been shown to produce several potentially cy-
totoxic molecules, including superoxide anion, nitric oxide, and proin-
flammatory cytokines [66] [67], shown in figure 1.7. Lipopolysaccha-
ride (LPS), interferon γ (INFγ), and β-amyloid [68] are among the
stimulators for the production of harmful factors from microglia. Re-
active oxygen species (ROS) including superoxide anions, hydroxy rad-
icals, and hydrogen peroxide are generally hazardous, particularly to
myelin and its forming cells (oligodendrocytes) owing to their capa-
bility of inducing lipid peroxidation. LPS and phorbol-12-mynstate-
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Figure 1.8: Exemples of signals and modulators of microglia activation
adapted from Uwe-Karsten Hanisch, Helmut Kettenmann 2007 [51].
13-acetate (PMA) are stimulators of ROS production from cultured
microglia. Nitrogen oxides such as NO are highly reactive free radi-
cals, of which nitrite peroxide is the strongest species. These radicals
are believed to inhibit respiratory enzymes, oxidize the SH group of
proteins, and enhance DNA injury, finally resulting in neuronal cell
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death. LPS and β-amyloid are known stimulators of NO production
from microglia. In the presence of INFγ, β-amyloid synergistically
stimulates the production of NO and TNFα [69] in microglia.
Besides, recently it was demonstrated by Liddlelow and colleagues
a direct role of microglia on the astrocytes activation. They demon-
strated that a subtype of reactive astrocytes, named in their paper
A1, is induced by classically activated neuroinflammatory microglia.
They show that activated microglia induce A1 astrocytes by secreting
Il-1a, TNFα and C1q, and that these cytokines together are necessary
and sufficient to induce A1 astrocytes. A1 astrocytes lose the ability
to promote neuronal survival, outgrowth, synaptogenesis and phago-
cytosis, and induce the death of neurons and oligodendrocytes. Death
of axotomized CNS neurons in vivo is prevented when the formation of
A1 astrocytes is blocked. Finally, they have shown that A1 astrocytes
are abundant in various human neurodegenerative diseases including
Alzheimer’s, Huntington’s and Parkinson’s disease, amyotrophic lat-
eral sclerosis and multiple sclerosis [70]. Effector microglia might bet-
ter describe cells executing a number of adaptive responses to a given
challenge.
However, on the other hand, co-cultures of microglia and neurons
revealed that microglia did not kill healthy neurons in vitro, indicating
that their phagocytic properties are not necessarily dangerous for neu-
rons. Secondly, the effects of conditioned microglial medium (CMM)
on neurons were examined. The results showed the CMM expressed no
neurotoxicity. Rather, CMM significantly enhanced neuronal survival
and the neurite outgrowth of neocortical and mesencephalic neurons
[60].
In conclusion, activated microglia act primarily in the defence of
the brain, as brain scavengers, and in tissue remodeling, an immune
and/or immunoeffector role has also been proposed. Activated mi-
croglia are implicated in pathogenesis and inflammation. They have
also been shown to produce a variety of biological factors. Recent bio-
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chemical and neurobiological studies have revealed that activated mi-
croglia produce and secrete not only cytotoxic/harmful molecules but
also neurotrophic molecules including neurotrophins and neurotrophic
cytokines. As a whole, activated microglia appear to play a significant
role in pathological and regenerative states of the brain, expressing
both or either of two potentially opposing functions: cytotoxic and
neurotrophic actions.
1.3.1 Inflammation markers
Neuroinflammation, and to the same degree all inflammation, is a fun-
damental immune response designed to protect the body from harm,
arising from both endogenous and exogenous sources. Being the sen-
tinel immune cell of the brain, microglia play a role as first responders
to infections or tissue injuries and initiating an inflammatory response.
Using a full array of immune receptors, such as toll-like receptors
(TLRs), nucleotide binding oligomerization domains (NODs), NOD-
like receptors, and many scavenger receptors [71] [72], microglia (as
well as other CNS cells, such as astrocytes) are able to recognize harm-
ful stimuli and respond by producing inflammatory cytokines such as
TNFα, IL-6, IL-1β, interferon-γ (IFNγ), and several chemokines [73].
This cytokine production is essential for the polarization of microglia
into what has been termed a classically activated, M1, state [74]. Due
to this ability to respond to inflammatory cytokines, as macrophages
do, the microglia activation state started to be named in the same way
of macrophages. In particular, the term M1 parallels the Th1 termi-
nology used for T cells, and underscores the close relationship between
T cells and macrophages in the periphery. Interferon-γ produced from
Th1 cells was found to be instrumental in polarizing macrophages to
M1 state [74]. However, the ability to produce these cytokines does
not rest solely with T cells. Microglia and astrocytes have also been
observed to fill this role [75], demonstrating, at least in part, that
CHAPTER 1. INTRODUCTION 26
microglia can control their own polarization through autocrine and
paracrine means. For the evolution of these theories on macrophages
polarization see figure 1.9.
Figure 1.9: M1 and M2: the concept of macrophage polarization [76].
In many cases, this response is protective and is downregulated
once the damage or pathogen has been dealt with. However, dysreg-
ulated, long-term, or chronic inflammation can lead to tissue destruc-
tion [77] [7] as in the rappresentative figure 1.10.
Differently to proinflammatory M1 cells, alternatively activated
macrophages (M2) express cytokines and receptors that are implicated
in inhibiting inflammation and restoring homeostasis. This includes:
IL-10 to downregulate inflammatory cells, extracellular matrix pro-
tecting proteins like YM1, ornithine, and polyamines for wound re-
pair, and higher levels of receptors associated with phagocytosis, such
as scavenger receptors [78]. Just as the Th1 cytokine IFNγ has been
associated with induction of proinflammatory M1 macrophages, the
Th2 cytokine IL-4 has been associated with M2, or alternative, acti-
vation. Interestingly, it appears that when there is a lack of M2 cell
differentiation in the CNS, problems can arise. To properly understand
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Figure 1.10: Reactive microgliosis drives progressive neurotoxicity:
microglia can become overactivated and cause neurotoxicity through
two mechanisms. First, microglia can initiate neuron damage by recog-
nizing pro-inflammatory stimuli, such as lipopolysaccharide (LPS), be-
coming activated and producing neurotoxic pro- inflammatory factors.
Second, microglia can become overactivated in response to neuronal
damage (reactive microgliosis), which is then toxic to neighbouring
neurons, resulting in a perpetuating cycle of neuron death. Reactive
microgliosis could be an underlying mechanism of progressive neuron
damage across numerous neurodegenerative diseases, regardless of the
instigating stimuli [7].
the role microglia play in neurodegeneration, understanding their phe-
notypes is important. The functional effects of classical activation are
geared towards antigen presentation and the killing of intracellular
pathogens. Therefore, upregulation of many associated receptors and
enzymes reflects that purpose. For example, MHC II, CD86, and Fcγ
receptors are upregulated to allow for antigen-presenting activity of
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microglia and increased crosstalk with other immune cells [79]. In
addition, the ratio of particular cytokines has been used to identify
inflammatory macrophages and this observation could extend to mi-
croglia. For example, since M1 macrophages were found to be a key
source of IL-12 [80], it was suggested that IL12 High, IL-10 Low pro-
duction is a simple way to distinguish inflammatory cells [81]. Another
potential distinction and an important component of M1 microglia is
their ability to produce reactive oxygen species and reactive nitrogen
species [82]. A key microglial enzyme associated with this process
is inducible nitric oxide synthase (iNOS), which utilizes arginine to
produce nitric oxide [83]. However, even though it seems straightfor-
ward to identify M1 cells based on these characteristics, classifying
these cells in vivo has proven to be more challenging, reflecting the
plastic nature of microglia. Even for M2 cells the classification is not
clear. In fact, there are many efforts to identify unique subgroups
with different functions. Division of M2 cells is based on observations
that stimulation with various cytokines yields different sets of receptor
profiles, cytokine production, chemokine secretion, and function [81].
Even though the profiles of these cells are diverse, the one feature that
places them all in the M2 classification is that they express mediators
or receptors able to downregulate, repair, or protect the body from in-
flammation [84]. The original alternatively activated macrophage was
classified based on expression of the mannose receptor [85]. Since then
a panel of different markers has been identified as M2 specific. One of
the best characterized markers is the enzyme arginase 1 (Arg1) [86],
which converts arginine to polyamines, proline, and ornithines that
can contribute to wound healing and matrix deposition [87]. Thus,
iNOS and Arg1 represent a relatively straightforward set of markers
to distinguish M1 from M2 phenotypes, as shown figure 1.11.
Other markers used for identifying M2 cells include Ym1, a heparin-
binding lectin [89], FIZZ1, which promotes deposition of extracellular
matrix [90], and CD206, a mannose receptor [85]. Despite the benefit
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Figure 1.11: Diagram of activation states of microglia based on in-
flammatory profile and effector function. Based upon peripheral
macrophage nomenclature, M1 and M2 polarization states of microglia
have been proposed as a framework to evaluate the heterogeneity of
responses with recent evaluations suggesting a framework focused on
the inducing stimuli [88].
of having specific markers, using just one or two is limiting and ignores
the overall diversity of M2 phenotypes. Another way to classify the
function and phenotype of M2 cells is based on the cytokines that in-
duce them. The prototypical cytokine used to first induce alternative
activation was IL-4 [85]. Both IL-4 and the closely related cytokine
IL-13 signal through IL-4Rα to induce a host of downstream processes
that lead to potent anti-inflammatory functions, such as Arg1 upreg-
ulation, inhibition of NF-kB isoforms, and production of scavenger
receptors for phagocytosis [79] [91] [92]. This type of activation has
been classified as M2a. The main function of this response appears
to be suppression of inflammation. A second state of alternative acti-
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vation is based on macrophages exposed to IL-10, glucocorticoids, or
TGF-β. This phenotype is classified as M2c [81] [93]. Originally, this
state was described as being deactivated but that is not a particularly
useful description. Instead of having no function, deactivated M2c
macrophages appear to be involved in tissue remodeling and matrix
deposition after inflammation has been downregulated [81]. A third
sub-class of M2 activation has been observed following exposure to
immune complexes and stimulation of TLR. This class is termed M2b
or Type II [81] [94]. Of these three classes, M2b macrophages are
the least understood. Interestingly, they more closely resemble M1
macrophages, owing to the lack of any M2 specific markers, such as
Arg1, YM1, or FIZZ1. However, they do express the typical IL-10
High, IL-12 Low M2 cytokine profile [95]. Moreover, they have higher
levels of MHCII and CD86, suggesting that they retain their ability
to stimulate T cells [94].
An important consideration regarding M2 phenotypes is that these
states were typically elucidated in vitro following exposure to one or
two stimuli. This does not represent the complex environmental milieu
seen in tissue. Therefore, some investigators have cautioned against
this classification into distinct subtypes and instead propose that M2
cells should be viewed as a spectrum of phenotypes [95]. This de-
tailed classification of M2 cells has been primarily carried out in the
periphery. Whether or not this will extend to brain resident microglia
is yet to be seen. Furthermore, microglia are not macrophages that
migrate into the brain, but instead are known to represent a distinct
population of resident tissue mesenchymal cells that populate the CNS
during early development [32] [33]. Importantly, because the origins
and responses of microglia and macrophages are different, the roles
they play in mitigating or propagating pathology could be different as
well.
Moreover, some other markers have been variously used as indica-
tors of microglial activation but the limitations of their use are seldom
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recognized. Important among these limitations is that several (if not
all) of the markers are not unique to microglia and that, except in par-
ticular circumstances for example where pure microglial cultures are
used, their upregulation may not reflect changes in microglia alone
(figure 1.12).
Figure 1.12: Proposed cell surface markers of microglial activation
[49].
It is also important to recognize that, to a large extent, studies re-
port changes in expression of cell surface markers under various condi-
tions with minimal assessment of functional change and therefore the
coupling of phenotype and function remains a challenge.
1.3.2 Phagocytosis and pinocytosis
Microglial cells are the professional phagocytes of the CNS tissue. This
function is important for the normal brain, during brain development,
and in pathology and regeneration [28]. As for other microglia func-
tions, such as the inflammatory cytokines secretion, also for phago-
cytosis there is no obvious concordance with whether it is beneficial
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or detrimental for tissue health. As I described previously, microglia
cells are highly sensible to different stimuli of the environment. As
these cells change their motility, their surface receptors, the release
of soluble chemokines and cytokines, they also change the ability of
up-taking debrees. Based on the type of debris, microglia can use
phagocytosis or pinocytosis to take them up [28].
Endocytosis can be classified in two types: the clathrin-dependent
and clathrin independent endocytic pathways. The clathrin-dependent
endocytic pathway requires the recruitment of endocytosed molecules
into clathrin-coated pits that are around 100 nm in diameter [96].
Phagocytosis and pinocytosis are two clathrin-independent endocytic
processes that occur in phagocytes, and both create large endocytic
vacuolar compartments (≥0.2 µm) through organized membrane move-
ments and actin polymerization [97]. Nevertheless, distinct models
and molecular mechanisms have been suggested for the formation
of phagosomes and pinosomes [97]. The well-studied Fc receptor-
mediated phagocytosis is guided by a zipper-like progression of receptor-
initiated membrane invagination that is shaped by the geometry of the
internalized particle, whereas pinosomes, which may vary from 0.2 to
10 µm in diameter, are suggested to form spontaneously or in response
to growth factor receptor activation from membrane ruffles that close
at their distal margins to engulf extracellular fluid [97] [98]. Phago-
cytosis is applied in many physiological and pathological processes,
including development, innate immunity, and the entry of pathogens
into host cells [97] [98].
The activity of microglial phagocytosis relies on ”eat me” signals
expressed on the cell surface of dying cells [99] and on specific receptors
expressed on microglia cell surface. Downstream signaling pathways
are activated and contribute to the reorganization of actin protein and
engulfment of harmful microparticles (Fig.1.13).
Microglial phagocytosis may need different types of receptors to
initiate function [100], there are two distinctive types of receptors:
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Figure 1.13: Signaling pathways involved in microglial phagocytosis.
A Extracellular nucleotides, such as UDP and UTP, trigger microglial
phagocytosis through P2Y6R/ PLC/InsP3 pathway. B Apoptotic de-
bris induces phagocytosis via TREM2/DAP12/ERK/PKC pathway.
C Endogenous or ectogenic detriments, such as LPS, viral nucleotides,
α- synuclein, and f-Aβ, provoke phagocytosis by microglia via TLRs
through activation of MyD88-dependent IRAK4/p38/ scavenger re-
ceptors pathway or MyD88-independent actin- Cdc42/Rac signaling
pathway.
- the first with a high affinity for foreign microbial pathogens and
which simultaneously stimulates a pro-inflammatory response in the
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phagocytes [101], such as Toll-like receptors (TLRs). - The second type
of receptors can, recognize apoptotic cellular substances and stimulate
an anti-inflammatory response in phagocytes. Triggering receptor ex-
pressed on myeloid cells 2 (TREM2) is an example of this second
type of receptors. The phagocytosis triggered by TREM2 takes place
without inducing inflammation and it is one of the major beneficial
functions of phagocytes (figure 1.13).
TREM2 is a kind of pattern receptor specific for polyanions and lo-
cates mainly on the cell surface of osteoclasts in bones and in microglia
of the CNS [102].
TREM2 [103] is a 40-kDa type I membrane glycoprotein with a
single extracellular immunoglobulin-like domain, one trans-membrane
domain, and a short cytoplasmatic tail. Its transmembrane domain
interacts with the adaptor protein TYROBP/DNAX-activating pro-
tein of 12 kDa (DAP12) via electrostatic interaction [103]. DAP12
is a type I transmembrane protein, which acts as a signaling adaptor
protein for TREM2 and for other cell surface receptors.
TREM2 seems to be involved in two signaling pathways in mi-
croglia: phagocytosis and proinflammatory cytokines secretion. In-
deed, increased expression of TREM2 on microglia has been associ-
ated with enhanced phagocytosis and increased alternatively activated
M2 protective microglia, while absence of TREM2 expression on mi-
croglia does exactly the opposite, impairing phagocytosis and increas-
ing the proinflammatory phenotype [104]. TREM2 phagocytic func-
tion is not associated with inflammation. In addition to up-regulating
of chemokine synthesis and mediating protective phagocytosis of apop-
totic cell debris, activation of TREM2 receptors suppresses secretion
of pro-inflammatory factors such as cytokines and ROS [102]. On mi-
croglia TREM2 via binding to DNAX- activation protein 12 (DAP12),
an ITAM-containing adaptor protein, triggers the reorganization of F-
actin and phosphorylation of ERK/MAPK, mediating the clearance
of apoptotic neurons [105] [106].
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The paramount importance of these receptors has recently become
clear as patients with a loss of function mutation of either TREM2 or
DAP12 develop an inflammatory neurodegenerative disease leading to
death at the fourth or fifth decade of life. Nasu-Hakola disease, a sys-
temic bone cystic disorder with progressive presenile dementia followed
by extensive sclerosis in the front-temporal lobe and the basal ganglia,
occurs due to genetic mutation of TREM2 and DAP12 resulting in
aberrant TREM2/DAP12 signaling pathway. Thus, even though the
ligand of TREM2 is unknown, microglial TREM2/DAP12-mediated
phagocytosis appears to be an essential function for CNS tissue ho-
moeostasis [104].
Besides these two types of receptors, some others including Fc re-
ceptors, complement receptors [107], scavenger receptors (SR), pyrim-
idinergic receptor P2Y, G-protein coupled, 6 (P2RY6), macrophage
antigen complex 2 (MAC-2), mannose receptor [108], and low-density
lipoprotein receptor-related protein (LRP) receptor also participate in
microglial clearance of misfolded, apoptotic cells and dead neurons in
both acute and chronic brain injury [109].
Furthermore, TLRs are a class of proteins that play a key role in
the innate immune system and the digestive system. TLRs are single,
membrane-spanning, non-catalytic receptors usually expressed in pe-
ripheral sentinel cells, such as macrophages and dendritic cells, that
recognize structurally conserved molecules derived from microbes. An
example is proposed by TLRs 1-9, which belong to interleukin (IL)-1R
super-family and that are expressed exclusively on antigen presenting
cells including microglia [110], macrophages, antigen presenting den-
dritic cells, and on cerebral parenchyma cells including neurons, oligo-
dendrocytes, and astrocytes. TLRs not only trigger the recognition
of pathogen-associated molecular patterns (PAMPs), such as LPS or
viral nucleotides, but also recognize so called danger-associated molec-
ular patterns (DAMPs), such as deposited amyloid β (Aβ) fibril and
α-synuclein [111] [112], they are host biomolecules that can initiate
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and perpetuate a noninfectious inflammatory response. In contrast,
PAMPs initiate and perpetuate the infectious pathogen-induced in-
flammatory response. TLR4-, TLR2-, and TLR9-dependent signaling
pathways are involved in mediating microglial phagocytosis of neuro-
toxic Aβ deposits in AD brain and exert a protective role in nerve re-
generation [113] [114]. It has been reported that TLRs regulate phago-
cytosis through myeloid differentiation factor 88(MyD88)-dependent
and MyD88-independent signaling pathways. The MyD88-dependent
pathway is triggered by TLRs through activation of IL-1 receptor-
associated kinase (IRAK)-4 and MAP p38, resulting in up-regulation
of scavenger receptors [115]. On the other hand, TLRs also regu-
late phagocytosis by a MyD88-independent actin-Cdc42/Rac pathway
[116].
Pinocytosis can be triggered by ”drink me” signals, since in the
pinosomes particles are small and a part of the extracellular fluid is
also included. It can be subdivided in micro-and macro-pinocytosis.
Micropinocytotic vesicles are no larger than 0.1 µm in diameter
and may be caveolin-coated. Micropinosome formation is indepen-
dent of actin and occurs within cholesterol-rich lipid domains of the
plasma membrane [117], while macropinocytosis results in the forma-
tion of vesicles that are between 0.2 µm and 5.0 µm in diameter and
are created by the enclosure of membrane ruffles. Macropinocytosis
was first described morphologically by Warren Lewis in 1931 [96] and
it is a clathrin-independent endocytic route, a regulated form of endo-
cytosis that mediates the non-selective uptake of solute molecules, nu-
trients and antigens. Macropinocytosis is a signal-dependent process
that normally occurs in response to growth factor stimulation, such
as macrophage colony-stimulating factor-1 (CSF-1), epidermal growth
factor (EGF) and platelet-derived growth factor or tumour-promoting
factor, such as phorbol myristate acetate (PMA) [118] [119]. How-
ever, some specialised cell types such as antigen-presenting cells are
capable of constitutive macropinocytosis [120] [121]. Macropinocyto-
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sis involves actin- mediated membrane ruffling of the plasma mem-
brane leading of the formation of lamellipodia. Most of these retract
back into the cell. However, a subset of lamellipodia may fold back
onto themselves and fuse with the basal membrane creating large,
irregular shaped vesicles named macropinosomes (Figure 1.14). How-
ever, there is, no consensus on the proportion of membrane ruffles
that end up forming macropinosomes. Macropinosomes are distinct
from other forms of endocytic vesicles. Macropinocytic vesicles have
no apparent coat structures and although heterogenous in size, they
are generally considered to be ≥0.2 µm in diameter [122] [123], a
size considerably larger than clathrin coated vesicles. Owing to the
large size of macropinosomes, which can be up to 5 µm in diameter,
macropinocytosis provides cells with a way to non-selectively inter-
nalise large quantities of solute and membrane. Thus, in addition to
its size, macropinosomes can also easily be identified through the use
of fluid phase markers, such as Lucifer Yellow, horseradish peroxidase
and dextran. Once formed, macropinosomes undergo a maturation
process. However, this maturation is unlikely to occur through a path-
way common to all cells (see in figure 1.14).
Macropinosomes form in response to treatment with CSF-1 [124].
They acquire and loose different endocytic protein markers as they
migrate centripetally toward the lysosome. Within 1 min of colony-
stimulating factor-1 treatment, macropinosomes become positive for
transferrin receptors. These are considered to be macropinosomes at
an early maturation stage, within 2-4 min and the macropinosomes are
devoid of transferrin receptors and begin to acquire Rab7, a marker
of the late endosomes. Rab7-staining coincides with the presence of
lysosomal glycoprotein A (lgp-A). Finally, the macropinosomes merge
with the existing tubular lysosomal compartments [125] and fuse with
the plasma membrane, recycling its content to the exterior of the cell
[122] [126].
As macropinocytosis is associated with actin-dependent ruffling of
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Figure 1.14: Pathway of macropinocytosis. Macropinocytosis in-
volves actin cytoskeleton rearrangement at the plasma membrane
leading to the formation of membrane ruffles. Ruffles may fold
back onto themselves and fuse at the base of plasma membrane,
trapping solute and soluble substances in macropinosomes. Early
maturation of macropinosomes involves extensive tubulation result-
ing in mature macropinosomes that are more spherical. Content
of the macropinosomes are then either degraded at the late endo-
some/lysosome or recycled back to the plasma membrane. The cy-
toskeleton is depicted as black lines [96].
the plasma membrane, this pathway has been implicated in cell motil-
ity. Macropinocytosis is also considered important in the chemotactic
response of highly mobile cells.
A key difference between clathrin-dependent endocytosis and macropinocy-
tosis is that the latter requires actin cytoskeleton reorganisation. Treat-
ment with phosphoinositide 3-kinase (PI3-kinase) inhibitors or cy-
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tochalasin, an actin-disrupting agent [127] has been shown to inhibit
macropinocytosis but not the clathrin-dependent endocytic pathway
[128] [129]. The dynamics of actin cytoskeleton during macropinocy-
tosis has been visualised in cells expressing fluorescently labelled actin
probes such as coronin. Coronin is an actin-associated protein, which
has a role in controlling actin dynamics during processes such as cell
motility, phagocytosis and cytokinesis [130]. In a separate experiment,
the dynamics of actin cytoskeleton was observed using GFP-actin-
binding domain probe binding specifically to F-actin, a structure also
recognised by phalloidin [131] [132]. The F-actin probe remained asso-
ciated with the macropinosome but was completely lost 30-50 seconds
after vesicle closure [131].
Araki et al. [133] investigated the distribution of F-actin in mouse
macrophages using actinin-4, a non-muscle form of α-actinin [133].
α-Actinin is an actin-binding protein, which cross-links F-actin into
bundles or connects F-actin to the plasma membrane. Immunofluores-
cence analyses revealed that lamellipodia stained positive for actinin-4.
Actinin-4 was also associated with dextran-labelled macropinosomes
and this association was found to decrease as the macropinosome ma-
tures [133]. These examples clearly depict the importance of actin
cytoskeleton reorganisation during macropinocytosis. Therefore, com-
ponents of signal transduction pathways linking receptor stimulation
to actin cytoskeleton remodelling are also implicated as regulators of
macropinocytosis as in table 1.15.
The remodelling of the cytoskeleton during macropinocytosis re-
quires also the activity of PI3-kinase [133] [134] [135]. In the case
of bone marrow-derived macrophages, PI3-kinase activity was not re-
quired for cell surface ruffling but rather for the closure of macropinosomes
[133]. PI3-kinase is a core signalling component in multiple signal
transduction pathways such as endocytosis, membrane traffic and cell
proliferation and inhibition of its activity will result in a range of other
effects. Amiloride or its more potent counterpart, dimethyl amiloride,
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Figure 1.15: Regulators of macropinocytosis and their respective sub-
cellular localisation during macropinocytosis [96].
is an inhibitor of the Na+/H+ exchanger pump in the plasma mem-
brane. It has been reported to selectively block macropinocytosis, and
not the clathrin-dependent endocytic pathway, when used at the ap-
propriate concentration [126] [136]. Thus, amiloride is gaining pop-
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ularity as a tool to study macropinocytosis. It has recently been
proposed that macropinocytosis is not directly sensitive to amiloride;
rather, macropinocytosis is affected by acidification from excessive lo-
calised H+ production at the site of macropinocytosis when the reg-
ulatory action of Na+/H+ exchanger pump is impaired by amiloride.
Acidification does not inhibit receptor activation or PI3-kinase local-
isation and activation but it does affect downstream localisation and
activation of Rac1 and Cdc42, GTPases required for actin remod-
elling [136]. Members of the sorting nexin (SNX) family have been
localised to macropinosomes and also implicated in macropinosome
formation. There is a direct relationship between the level of cell
surface SNX5 protein and macropinocytic activity, highlighting the
role for this sorting nexin in driving this signal-activated endocytic
pathway. In a recent study, 12 members of the SNX-PX-BAR fam-
ily were screened in an assay to determine the effect of their over-
expression on macropinosome formation [137]. SNX1, SNX5, SNX9,
SNX18 and SNX33 were all found to enhance macropinosome forma-
tion, an effect that appeared dependent on the increase in PI(3,4,5)P3
levels, which is regulated by PI3-kinase activity [137]. PI3-kinase,
Ras, Rac1 and Cdc42, as well as sorting nexins, are some examples
of macropinocytic regulators. Additional molecules, which are com-
ponents of the signal transduction pathway, and which have been im-
plicated in macropinocytosis are listed in table 1.15. Nonetheless it is
unclear how these different components are collectively organised to
regulate the process of macropinocytosis.
1.4 Microglia and neurons interaction: Spine prun-
ing and Synaptic Stripper
Recent findings challenge the concept that microglia solely function in
disease states in the CNS. Rather than simply reacting to CNS injury,
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infection, or pathology, emerging lines of evidence indicate that mi-
croglia sculpt the structure of the CNS, refine neuronal circuitry and
network connectivity, and contribute to plasticity. These physiological
functions of microglia in the normal CNS begin during development
and persist into maturity. Furthermore, both resting and activated mi-
croglia (as defined by a morphological phenotype) have physiological
functions even in the absence of pathologies. Consequently, the con-
cept of resting and activated microglia is misleading because multiple
phenotypic stages of these cells can influence the neuronal structure
and function to maintain neural circuits.
In the absence of pathological insults, the highly dynamic motility
of microglia is specifically targeted to synaptic structures as shown in
figure 1.16.
In the somatosensory and visual cortex two-photon microscopy re-
vealed that microglial processes make brief, repetitive contacts with
synapses at a frequency of about one per hour. These interactions were
visualized by in vivo two-photon imaging in the Iba-1-EGFP/Thy-1-
GFP double-transgenic mice in which microglial cells and neuronal
structures can be simultaneously visualized. Wake et al. in 2009 re-
ported that the microglial processes appear in a close proximity to
presynaptic boutons, where they remain for about 5 min and then
retract. In the visual cortex, these structural interactions are activity-
dependent, as their frequency was reduced by decreased neuronal ac-
tivity following either binocular eye enucleation, injection of tetrodotoxin
into both retinae or a reduction of body temperature [138]. By com-
bining two-photon in vivo imaging with immunohistochemistry and
three-dimensional reconstructions obtained from serial section electron
micrographs as shown in figure 1.16B, a rather specific apposition of
microglial processes to pre as well as postsynaptic compartments was
found in the visual cortex of juvenile mice [139]. Process extrusions
were typically associated with small and transiently growing dendritic
spines. Again, neuronal activity modulated microglial behavior: light
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Figure 1.16: Dynamic Interaction of Microglial Processes with the
Quadripartite Synapse: (A) Microglial processes (red) dynamically
contact the cellular compartments of the tripartite synapse: pre- and
postsynaptic neuronal terminals (in brown) as well as the enwrapping
perisynaptic astroglial process (in blue). (B) The electron micrograph
(EM) specifically shows a microglial process (m) contacting both the
pre and postsynaptic compartment. The EM image is modified from
Wake et al. (2009) [138].
deprivation reduced the motility of microglial processes and increased
their association with larger dendritic spines. Re-exposure to light re-
versed these behaviors and microglial processes enwrapped synapses
more extensively [139]. In response to neuronal activity, microglia
steer their processes toward active synapses (as shown in Figure1.17A),
which facilitates contact with highly active neurons. The mechanism
of this steering of microglia to active synapses is currently not known.
Thus microglial cells respond to altered sensory experience and
it remains an open question whether the interactions play any role
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Figure 1.17: Microglia Control Neuronal Activity, Programmed Cell
Death, and Synapse Connectivity. Taken from [24].
in experience-dependent modification or elimination of synapses, in
the developing as well as in the adult CNS. The molecular cues that
attract microglial processes to the synapses remain largely unknown.
Considering these synapse modification or elimination that could be
affected by microglia during experience-dependent plasticity, the term
tripartite synapse was changed in quadripartite synapse, where pre-
post synaptic neurons, astrocytes and microglia modulate the synaptic
activity together.
Conceptually, microglial cells can affect neural networks either
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through removal of cellular and subcellular elements (by phagocytosis)
or through secreting various factors with transmitter, trophic or neu-
roprotective properties. The variety of neuroactive agents that can be
secreted by microglia cells has been mainly studied in cell culture, an
environment that triggers transformation of microglial cells into an ac-
tivated state. Thus, these factors are considered to be representative of
an activated state, with possible relevance to a more pathological acti-
vation. These include several types of cytokines (e.g., TNFα or ligands
for receptors such as CCR1, CCR3, CCR5, and CCR7 and CXCR1
or CXCR3), trophic factors like brain derived neurotrophic factor
(BDNF), the gaseous transmitter NO or neurotransmitters (ATP and
glutamate) (for review, see Kettenmann et al. 2011 [28]). Some of
these substances were reported to rapidly modulate neuronal function
by changing excitability and synaptic strength. Moreover, several fac-
tors known from pathology can mediate the interactions of microglia
with synapses in the healthy brain. Recent findings indicate that some
of these pathological factors mediate neuron-microglia crosstalk in the
developing or uninjured adult brain.
As described in the first chapter, the primitive myeloid progenitors
originating from the extra-embryonic yolk sac enter the nervous tissue
very early in embryonic development, being the first existing glial cells
(as both astrogliogenesis and oligodendrogliogenesis occur later in a
perinatal period) [29]. This initial migration coincides with the first
wave of embryonic synaptogenesis (which occurs, in rodents, around
embryonic day 14-15) that proceeds in the absence of astrocytes (which
assist and are indispensable for postnatal formation of synapses). In
this phase microglia can assist and even promote early synaptogenesis
through secretion of growth factors [140].
Miyamoto et al. in 2016 [141] demonstrated how the microglia-
neurons contact induces synapse formation in the developing somatosen-
sory cortex. Using in vivo multiphoton imaging of layer 2/3 pyramidal
neurons in the developing somatosensory cortex, they demonstrated
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that microglial contact with dendrites directly induces filopodia forma-
tion. This filopodia formation occurs only around postnatal day 8-10,
a period of intense synaptogenesis and when microglia have an acti-
vated phenotype. Filopodia formation is preceded by contact-induced
Ca2+ transients and actin accumulation, as shown in figure 1.18 [141].
Figure 1.18: Scheme of microglia functions during synaptogenesis. (a)
Sequence of proposed cellular events during synapse formation: Mi-
croglial contact initiates a rise in local [Ca2+]i resulting in actin ac-
cumulation and filopodia formation. Some filopodia find presynaptic
partners and mature into functional synapses. (b) Schematic graph de-
picting a change in microglia phenotype and function, from immature
or activated microglia inducing filopodia formation and enhancing spe-
cific circuit synapse formation during early synaptogenesis, followed
by a putative role in synapse elimination by more mature, quiescent
microglia in the latter period of circuit formation [141].
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Inhibition of microglia by genetic ablation decreases subsequent
spine density, functional excitatory synapses and reduces the relative
connectivity from layer 4 neurons [141] demonstrating how microglia
cells are crucial elements to the spine formation.
During later, pre and postnatal development, microglial processes
actively engulf synaptic structures and exert a major role in control-
ling the number of synapses through synaptic pruning. The chemokine
fractalkine plays a role in chronic pain, inflammation, and Alzheimer’s
disease and it is released by neurons and endothelial cells [142] [143].
In the brain, fractalkine receptors are expressed specifically by mi-
croglia and fractalkine receptor-driven EGFP expression has become
a reliable marker for identifying microglial cells [46]. In mice deficient
for this receptor, there is a transient increase in the spine density dur-
ing development, suggesting an underlying deficit in synaptic prun-
ing. Depletion of fractalkine receptor also increased the frequency of
miniature excitatory postsynaptic currents recorded in the hippocam-
pus. This demonstrates that deficits in microglia function result in
synaptic changes [3].
Cunningham and colleagues investigated the function of microglial
cells in the developing cerebral cortex of prenatal and postnatal macaques
and rats showing that microglia limit the production of cortical neu-
rons by phagocytosing neural precursor cells. They show that mi-
croglia selectively colonize the primate sub ventricular zone (SVZ) and
phagocytose neural precursor cells as neurogenesis nears completion.
These data demonstrate that microglia play a fundamental role in reg-
ulating the size of the precursor cell pool in the developing cerebral
cortex [144]. Paradoxically, eliminating microglia is found to increase
apoptosis of lamina V cortical neurons [145].
As microglia are phagocytic, it has long been assumed that their
primary role in CNS development is to engulf and clear the bodies of
neurons that die as a result of programmed cell death, a mechanism
that eliminates the excess of neurons generated during normal develop-
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ment [146]. However, microglia are not simply reactive waste collectors
in development, but rather, they are active neuronal killers, assassi-
nating neurons inducing apoptosis (figure 1.17B). Several molecular
mechanisms by which microglia can directly instruct neuronal apop-
tosis have been identified in different CNS regions: (1) the release
of superoxide ions in the cerebellum [146], (2) the secretion of nerve
growth factor in the retina [147], or (3) production of TNFα in the
spinal cord [148]. In the hippocampus of neonatal mice, microglia-
induced neuronal apoptosis is dependent upon complement receptor 3
CR3 [149] and upon other cell surface receptors that transduce kill-me
and eat-me signals [150] expressed by neurons that are committed to
die. Activation of these microglial cell surface receptors initiates in-
tracellular downstream signaling through KARAP/DAP12, ultimately
triggering the release of neurotoxic agents. The commitment of a par-
ticular neuron to die may be made cell autonomously. Alternatively,
microglial cells may also participate actively in the induction of kill-me
and eat-me signals in the neurons [146]. The quantity of neuronal pre-
cursors, as well as of differentiated neurons, are regulated by microglia
[144].
Thus, it could be speculated that a microglial dysfunction or any
factor that alters the number or activation state of microglia can pro-
foundly affect neural development and could be responsible for devel-
opmental disorders.
Importantly the microglia physiological and pathological phago-
cytosis show morphological specificity: the phagocytosis of synaptic
material or of apoptotic cells is performed by microglial processes or
en passant branches forming ball-and-chain structures [151] without
affecting the ramified microglial phenotype.
During development, CNS initially produces excessive numbers of
neurons and neuronal axons typically make exuberant synaptic con-
nections to more target neurons than those that are maintained in
the fully developed nervous system. The projections are refined and
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sculpted to the mature architecture as large numbers of synapses are
eliminated. Synaptic pruning has long been known to be dependent
on neuronal activity [152], but over the past decade, microglia have
emerged as critical for this process (figure 1.17C). Indeed, in the cortex
the peak of microglial density coincides with the peak of synaptogene-
sis [153]. Developmental synaptic pruning has been extensively inves-
tigated in the retinogeniculate system where the initial widespread and
overlapping projections of retinal ganglion cells (RGCs) are progres-
sively segregated into stereotyped eye-specific territories [150]. Prun-
ing of inappropriate RGC synapses in the lateral geniculate nucleus
(LGN) is achieved by microglial engulfment of the synapses, both pre-
and postsynaptic elements, in a retinotopically appropriate manner.
The phagocytosis of inappropriate synapses is lost in mice lacking com-
plement receptor 3 (CR3), which is activated through the well-known
classical complement cascade that begins with C1q and proceeds to
opsonization of C3. In the CNS, CR3 is expressed only by microglia.
Mice lacking C1q, CR3, or C3 have sustained defects in eye-specific
segregation [154] [155], implicating complement-dependent signaling
as necessary for the synaptic elimination.
In addition to synaptic pruning, microglia are required for proper
maturation of excitatory synaptic transmission. In CA1 hippocampal
pyramidal neurons, the frequency and amplitude of miniature excita-
tory postsynaptic currents (mEPSCs) are increased in CX3CR1 null
mice as compared with wild-type littermates around postnatal day 13
(P13) [3]. Mice lacking CX3CR1 show persistent alterations in excita-
tory transmission, but no differences have been found with inhibitory
synaptic transmission [156].
The impairments caused by lack of CX3CR1 are suggestive of a
role for microglia in maturation of synaptic functioning (Figure1.17
C).
Moreover, several studies indicate that microglial cells can influ-
ence synaptic plasticity. Examples include modulation of the NMDA
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receptor glycine binding site by microglia [157], signaling by fractalkine
and its receptor [3] [158], modulation of Cl- gradient in neurons through
microglial BDNF release [159] and purinergic signaling [160]. However,
the best documented role of microglia in controlling neural network
functions comes from the analysis of the effects of the proinflammatory
cytokine TNFα on synaptic connectivity.
Incubating hippocampal slices with TNFα increased the ratio of
AMPAR- to NMDAR-mediated synaptic currents without affecting
long-term potentiation (LTP) or long-term depression (LTD). By us-
ing cocultures of neurons and glia from wild-type or TNFα knockout
mice, the source of TNFα was attributed to glia. Thus, by modu-
lating TNFα levels, neuroglia actively participates in the homeostatic
activity-dependent regulation of synaptic connectivity [161].
More recent data [162] demonstrate that the TNFα is exclusively
generated by microglia, and not by the astrocytes. Microglial TNF-
α and microglial ATP act in concert to trigger adjacent astrocytes to
release ATP. Astroglial ATP subsequently amplifies the microglial sig-
nal and promotes astroglial release of glutamate that directly affects
synaptic transmission through presynaptic metabotropic glutamate
receptors [162]. These experiments performed in the hippocampus
provide important insights into microglia role in modulating synaptic
plasticity.
A similarly complex function of microglial ATP release, purinergic
receptor activation, Ca2+ signaling, and subsequent glutamate release
has been also described in zebrafish, though not in physiological con-
ditions but during the onset of an acute injury [163].
Sipe and colleages demonstrate that microglia respond to monoc-
ular deprivation during the critical period, altering their morphol-
ogy, motility and phagocytic behaviour as well as interactions with
synapses. To explore the underlying mechanism, they focused on
the P2Y12 purinergic receptor which is selectively expressed in non-
activated microglia and mediates process motility during early injury
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responses. They found that the disruption of this receptor alters
the microglial response to monoculardeprivation and abrogates ocu-
lar dominance plasticity. These results suggest that microglia actively
contribute to experience-dependent plasticity in the adolescent brain
[2].
In different pathologies microglia acquire distinct functional states
and, during the disease progression, microglial cells modify and change
their activated phenotype and their interaction with neurons. Acti-
vated microglia specifically interact with neurons and influence their
survival either in a positive or in a negative direction. Microglia can
physically contact injured neurons and remove synapses, a process
termed synaptic stripping: in some instances, entire dendritic trees
are eliminated. During the activation state microglial cells release di-
verse substances such as reactive oxygen species, cytokines or growth
factors, which can influence the pathological process during acute and
chronic phases as well as during subsequent regeneration. This process
was first recognized in the facial nerve injury model [164]. Lesion to
the facial nerve (that carries axons of motoneurons located in the fa-
cial nucleus) triggers microglial activation, manifested by upregulation
of cytokines, cell adhesion molecules, extracellular matrix proteins,
transcription factors, and proteins of the major histocompatibility
complex. Activated microglial cells release neurotrophic factors such
as nerve growth factor (NGF), neurotrophin (NT)-4/5, transforming
growth factor (TGF)-β1, glial-derived neurotrophic factor (GDNF),
fibroblast growth factor (FGF), and interleukin (IL)-3, which affect
neuronal survival [165]. Microglia-derived factors also include proin-
flammatory mediators such as tumor necrosis factor TNFα, IL-6, or
nitric oxide (NO), which confer neurotoxicity. Microglial secretory ac-
tivity can vary depending on the pathologic context [51]. The specific
role of NGF release from activated microglia has not been investigated
and totally understood, but it is discussed in more detail the chapter
Microglia and Neurotrophins.
CHAPTER 1. INTRODUCTION 52
Conceptually, two types of signals control microglial behavior in
response to injury: find-me signals, attracting microglial cells to the
damaged site, and eat-me signals, allowing microglia to identify the
target and trigger phagocytosis. Another classification distinguishes
between on signaling, which includes factors newly appearing in the
pathologic context or are upregulated, and off signaling which includes
factors that disappear or are downregulated in pathology [166].
In the next chapters how microglia cells change their physiological
functions into pathological situation will be described in more detail.
2 Microglia in the Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative dis-
order of the elderly. It is characterized by progressive memory decline
and cognitive dysfunction, manifested histologically by the parenchy-
mal deposition of amyloid-beta (Aβ) plaques, the formation of neu-
rofibrillary tangles in the brain (particularly in the hippocampus and
cerebral cortex) and neuroinflammation [167] [168] [167] [168].
The senile plaques described by Alois Alzheimer in his original
case report result from the abnormal extracellular accumulation and
deposition of the Aβ; it is a fragment of a larger membrane-spanning
glycoprotein called amyloid precursor protein (APP) [169]. The physi-
ological function of APP protein in neurons is still unknown, probably
it has some role in plasticity [170]. Aβ is generated through pro-
teolytic processing of APP by β and γ secretase. The predominant
forms of Aβ in AD are 40 and 42 aminoacid peptides that undergo
conformational changes leading to the formation of intracellular and
extracellular fibrils [169] (see figure 1.19). Because of its higher rate of
oligomerization, Aβ 42 is more toxic than Aβ40. The cellular compo-
nents of the senile plaque include dystrophic neurites, astrocytes and
activated microglia [171].
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Figure 1.19: The plaque formation: The increase in production and/or
reduced clearance of Aβ, which is derived from the β-amyloid pre-
cursor protein (APP), is thought to be a central event in Alzheimer
disease (AD). Cleavage of APP occurs either in a non-amyloidogenic
(physiological) or in an amyloidogenic (pathological) fashion; only the
latter results in the production of Aβ. In the non-amyloidogenic path-
way, APP is cleaved first by α-secretase and then by γ-secretase,
whereas in the amyloidogenic pathway, γ-secretase cleavage of APP
is preceded by β-secretase cleavage, releasing Aβ into the extracellu-
lar compartment. The cleavage site used by γ-secretase in the amy-
loidogenic pathway determines whether the predominant Aβ40 or the
more aggregation-prone and neurotoxic Aβ42 species of the peptide
is generated. Aβ monomers may then go on to form oligomers or
other arrays, depending on mutations in the Aβ coding region of APP
and post-translational modificationsThe arrow thickness indicates the
likelihood of conversion of Aβ species or arrays [76].
Plaque-associated neuritic dystrophies represent the most notori-
ous evidence of Aβ-induced neurotoxicity and feature many of the
pathophysiological processes downstream Aβ.
The neurofibrillary tangles (NFTs) were first described by Alois
Alzheimer in his original autopsy case report as intraneuronal fila-
mentous inclusions within the perikaryal region of pyramidal neurons.
NFTs (present in neuronal cell bodies) and neuropil threads (present
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in neuronal processes) are intracellular structures composed predomi-
nantly of a hyperphosphorylated, aggregated form of the microtubule
binding protein, tau [172] [173] [174]. Tau is synthesized and pro-
duced in all neurons and is also present in glia. The normal function
of tau is to bind to tubulin and stabilize microtubules. However, in
AD, tau becomes hyperphosphorylated and this form of tau disso-
ciates from microtubules and has a tendency to self-aggregate, thus
forming NFTs in cell bodies and dystrophic neurites. In summary, the
major constituent of NFTs is the microtubule-associated protein tau,
which is aberrantly misfolded and abnormally hyperphosphorylated.
Invariably accompanying NFTs are the neuropil threads, which are
thought to result from the breakdown of dendrites and axons of the
tangle-bearing neurons.
In addition to plaques and tangles, other neuropathological and
neurochemical hallmarks of AD include loss of synapses and selective
neuronal cell death as well as decreases in markers for certain neuro-
transmitters. Neurons that are particularly vulnerable in AD include
those in layer II of the entorhinal cortex, the pyramidal layers (e.g.
CA1) of the hippocampus, and certain areas of the temporal, parietal,
and frontal neocortex [168]. Although the majority of the vulnera-
ble neurons use glutamate, the major neurotransmitter in the brain,
there is also loss/dysfunction of certain subcortical projection neurons
such as basal forebrain cholinergic neurons and noradrenergic neurons
in the locus ceruleous. The dysfunction of cholinergic neurons [175]
[176], which are involved in attention and memory, has been the basis
for cholinergic therapy in AD.
It is important to note that much of the cognitive dysfunction in
AD is not due to loss of one neurotransmitter but rather to disruption
of network connections between several key brain regions within the
limbic system and specific areas of the neocortex [177] [178].
Early neurochemical analyses of AD brain tissue revealed that the
enzymes that generate and metabolize acetylcholine are substantially
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depleted [176]. This finding fits well with the fact that the defining le-
sions of AD -the Aβ-containing neuritic plaques and the tau-containing
neurofibrillary tangles- are present in septal hippocampal and basal
forebrain-neocortical pathways that are cholinergic, and with the fact
that frank cell loss is observed in the projection neurons of these path-
ways [179]. Although deficits in numerous neurotransmitters (includ-
ing corticotropinreleasing factor, somatostatin, GABA, and serotonin)
accrue as the disease progresses, the early symptoms appear to corre-
late with dysfunction of cholinergic and glutamatergic synapses. Mor-
phometric study of temporal and frontal cortical biopsies, performed
within an average of 2 to 4 years of the onset of clinical AD [180],
revealed a 25 to 35% decrease in the numerical density of synapses
in biopsied AD cortex, and a 15 to 35 % decrease in the number of
synapses per cortical neuron. Even at the end of the disease, quanti-
tative correlations of postmortem cytopathology with premortem cog-
nitive deficits indicate that the latter is more correlated with synapse
loss than with the numbers of plaques or tangles, degree of neuronal
perikaryal loss, or extent of cortical gliosis [181].
Also in mice model the comparisons of transgenic lines having vary-
ing APP expression suggest that decreases in presynaptic terminals are
critically dependent on cortical Aβ levels, not on Aβ plaque burden or
APP levels [182]. Coherently with this finding, presynaptic terminals
are already significantly depleted in 2- to 4-month-old APP transgenic
mice as their soluble Aβ- levels rise, but before Aβ deposition (i.e.,
plaque formation) begins. This animal work fits nicely with growing
evidence that memory and cognitive deficits in MCI and AD patients
correlate far better with cortical Aβ levels than with plaque numbers
[183] and correlate best with the soluble pool of cortical Aβ, which
includes soluble oligomers [184] [185]. Even in very mildly impaired
patients, soluble Aβ levels in the cortex show a significant correlation
with degree of synaptic loss [185].
Moreover, several electrophysiological studies of young mice trans-
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genic for human APP with AD-causing mutations have revealed signif-
icant deficits in basal synaptic transmission and/or long-term poten-
tiation (LTP, an electrophysiological correlate of synaptic plasticity)
in the hippocampus, well before the development of microscopically
detectable Aβ deposits.
Another important element in AD pathology is represented by
ε4 APOE allele on chromosome 19. It is the strongest genetic risk
factor for developing Alzheimer’s disease. APOE is involved in the
normal catabolism of triglyceride-rich lipoproteins. One of the first
reports linking APOE to Alzheimer’s disease pathology was APOE
immunoreactivity in Aβ deposits and neurofibrillary tangles which, as
described before, are hallmarks of Alzheimer’s disease pathology [186].
In addition, polymorphisms in the transcriptional regulatory region of
APOE have been associated with Alzheimer’s disease [187]. APOE is
a 299 aminoacid protein that has three common isoforms in humans
that only differ by 1 or 2 aminoacids: APOE2 (Cys112 and Cys158),
APOE3 (Cys112 and Arg158) and APOE4 (Arg112 and Arg158).
The aminoacid substitutions affect the total charge and structure of
APOE, thereby altering binding to both cellular receptors and lipopro-
tein particles, and possibly changing the stability and rate of produc-
tion and clearance. APOE has high expression in the brain, where
it is produced primarily by astrocytes and microglia. Under certain
conditions, some APOE production can occur in neurons [188].
Population studies have demonstrated that APOE4 increases the
risk of developing Alzheimer’s disease (one allele imparts a threefold
increase in risk and two alleles impart a 12-fold increase in risk) [189]
and is also associated with an earlier age of Alzheimer’s disease onset
[190].
Many studies using cell culture and transgenic animals have inves-
tigated the potential mechanisms by which APOE4 may contribute to
Alzheimer’s disease. These include studies investigating the role that
APOE4 has as a pathological chaperone for Aβ, thus affecting the
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clearance and deposition of Aβ and ultimately contributing to plaque
formation [191] [192]. Other studies investigate alterations in tau phos-
phorylation, in neurofibrillary tangle formation [193] [194] and in lipid
metabolism causing inhibition of neurite extension [195]. The APOE4
isoform does not alter Aβ synthesis [192], but it can dramatically in-
crease Aβ deposition in animal models of Alzheimer’s disease [191]. In
accordance, in ApoE knock-in mice, clearance of Aβ40 from the CNS
to plasma is inhibited in an allele-specific manner (ApoE4>ApoE3 or
ApoE2), demonstrating the role of APOE in the clearance of Aβ; the
capacity of which depends on the isoform [196].
Collectively, these studies indicate that APOE is a contributing
factor for Alzheimer’s disease by acting as a chaperone for Aβ, which
affects the clearance and deposition of Aβ, ultimately contributing
to plaque formation. Any profound change in APOE production and
clearance, aspects that are affected differently in the various isoforms,
are likely to have a large effect on Aβ deposition and Alzheimer’s
disease pathogenesis. Moreover, as described APOE is produced pri-
marily by astrocytes and microglia, pointing to a central role of these
cells in the AD etiopathology.
The contribution of microglia in Alzheimer’s disease etiopathology
will be discussed in the next chapter, with special attention to the
multiple role of these cells and how the inflammation mediated by
microglia is crucial for the disease.
In this very complex system, who is the first effector of this disease?
Or better, is there one principal effector for this disease?
There are several hypotheses that could explain the onset of Alzheimer’s
disease but they will not be discussed into more detail in this thesis.
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2.1 Microglia Activation: β-Amiloide and Inflam-
mation
In this section, the important roles of β amiloide and inflammation on
microglia activity are discussed due to their important effect for AD
pathology.
A lot of literature describe the inflammation as a part of the causal
role in Alzheimer’s disease pathogenesis, and understanding and con-
trol of interactions between the immune system and the nervous sys-
tem might be a key for the prevention or delay of most late-onset CNS
diseases.
In fact, AD pathology is also characterized by an escalating in-
flammatory response, which is primarily driven by microglia. For
more than a decade, there have been data indicating that the immune
system may have a role in AD. However, the importance of inflam-
mation to AD pathogenesis has only very recently been appreciated,
and inflammation is now thought to contribute to and exacerbate AD
pathology [197] [198] [199] [200] [201] [202].
Neuroinflammation was assumed to occur only at late to end stages
of AD and possibly to represent merely an epiphenomenon. In particu-
lar, glial cell activation was thought to accompany but not significantly
contribute to amyloid pathology [202]. However, the spectrum of glial
cell actions and other immunerelated changes in AD had not been
fully dissected, and it is still far from being well understood. In the
last years, preclinical, genetic and bioinformatic data have shown that
activation of the immune system accompanies AD pathology and con-
tributes to the pathogenesis of this disease [203]. The identification of
associations between AD and mutations in genes encoding triggering
receptor expressed on myeloid cells 2 (TREM2) [204] [205] and myeloid
cell surface antigen CD33 [206] proved to be conceptually powerful, as
it was the first time that the link between immune alterations and AD
pathogenesis was supported beyond the purely descriptive level.
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Correlative analyses of the clinical symptoms that precede AD
(namely mild cognitive impairment (MCI)) and the presence of in-
flammatory changes (for example, in the cerebrospinal fluid (CSF))
have indicated a much earlier involvement of the immune system [207]
[208]. Moreover, one study [209] showed that systemic immune chal-
lenge triggered and drove the development of AD-like neuropathology
comprising Aβ plaques, tau aggregation, microglia activation and re-
active gliosis in wild-type mice, suggesting that immune actions can
precede AD-like pathology and are sufficient to cause it. The mod-
ulation of the neurodegenerative disease courses by specific immune
molecules in pre-clinical experimental approaches and the upregulation
of inflammatory genes in arrays on tissues derived from patients with
degenerative CNS diseases also point to a relationship between inflam-
mation and neurodegenerative disorders (including AD), and implicate
immune actions early in the pathogenic process [198] [200] [210] [211]
[212] [213]. These observations imply that immune processes may at
least at a given time point drive AD pathology independently of Aβ
deposition and sustain increased Aβ levels, thus exacerbating pathol-
ogy and culminating in a vicious, pathophysiological cycle, see figure
1.20; suggesting a very crucial role in the pathology for the mediators
of inflammation, as microglia cells.
Indeed, it was demonstrated that the microglia numbers increase
in the AD brain [214]. Nowadays it is well known that microglia in the
AD brain are located around plaques. The evidence for the presence
of microglia in senile plaques derives from immunohistochemical stud-
ies that examined also the brains of AD patients [215]. In contrast to
normal brains where microglia are distributed uniformly throughout
the gray and white matter [215], in AD brains microglia are clustered
in and around Aβ deposits [214]. Also the electron microscopy studies
have revealed that microglia are closely apposed to Aβ [216]. In some
instances, microglia contain intracellular deposits of Aβ, indicating
a possible role for these cells in the clearance and/or processing of
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Figure 1.20: The presence of Aβ can prime microglial cells; namely,
Aβ makes these cells susceptible to a secondary stimulus and/or pro-
motes their activation. Priming results in various functional microglia
phenotypes (indicated by different colours), presumably accompanied
with no or only minor morphological alterations and/or no (major)
cell-surface marker differences. In AD, Aβ sustains chronic activation
of primed microglia, which results in a constant production of in-
flammatory cytokines and chemokines; the cytokines and chemokines
maintain activation of the primed cells. This process results in a vi-
cious circle, which ultimately impairs microglia; moreover, it affects
surrounding CNS resident cells (astrocytes, oligodendrocytes and neu-
rons), possibly aggravating tau pathology, and finally causing neu-
rodegeneration and neuron loss. If these processes perpetuate over
a prolonged period, it forces microglia into a senescent, burn-out-like
(dystrophic) phenotype which is thought to be irreversible [76].
Aβ [217], as discussed in the next section. Similar to their associa-
tion with AD lesions in humans, microglia cluster around Aβ deposits
in the brains of transgenic mice with AD-like pathology. Quantita-
tive analysis of microglia as a function of distance from the center of
senile plaques in transgenic mice revealed a 2- to 5-fold increase in
microglia numbers in areas with plaques compared with neighboring
regions [218]. These studies in transgenic mice confirm that microglia
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accumulation in senile plaques is an integral part of the disease process
in AD and that microglia might have a role in the pathogenesis of AD.
Moreover, microglia in senile plaques are activated as a result of
their interactions with Aβ. In AD brains, microglia associated with
senile plaques express several markers of microglia activation. When
compared with microglia in normal brains or those in AD brains not
interacting with Aβ, senile plaque associated with microglia selectively
expressed the MHC class II molecule HLA-DR, a marker for mononu-
clear phagocyte activation [215].
The appearance of amyloid plaques in the brain coincides with
a dramatic phenotypic activation of the surrounding microglia which
also display increased immunoreactivity as CD11b, CD68, complement
receptor 3 and CD45 [219]. Postmortem brains from AD patients, as
well as brains from APP transgenic animals, display increased levels
of inflammatory cytokines as well as chemokines including IFNγ and
TNFα, IL-1β, IL-6, TGF-β, a peptide growth factor and chemokines,
macrophage inflammatory proteins -1α, -1β, -2, and most prominently
CCL2/monocyte chemotactic protein 1 [220] [221] [221] [214] [222].
Interaction of microglia with Aβ also leads to secretion of chemokines,
such as monocyte chemotactic protein-1 (MCP-1, also known as CCL2)
[223] and induction of mRNA for several additional chemokines, in-
cluding CCL4 and CXCL2 [223]. Aβ-stimulated microglia also pro-
duce reactive oxygen species (ROS) and reactive nitrogen species.
These cells also elaborate a number of other immune mediators in-
cluding macrophage colony stimulating factor and the complement
protein, C1q [224].
As in other pathological conditions, resident microglia in AD have
been shown to produce either inducible nitric oxide synthase (NOS2)
or arginase, as described in the chapter 1.3.1. The NOS2 expression
and arginase production were suggested to be marker of M1 and of
M2 phenotypes respectively [225].
Moreover, microglia produce a large diversity of mediators, some
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of which may be attractive targets for modulating neuroinflammation
in AD and thus, potentially, for ameliorating the disease course.
A study by Shaftel et al. [226] took an alternative approach and
examined the effects of sustained inflammatory signaling by over-
expressing the pro-inflammatory cytokine IL-1β in astrocytes. The
sustained IL-1β activation, which was expected to have detrimental
effects, resulted in a significant decrease in amyloid deposition in the
hippocampus of these mice. They found that IL-1β over-expression led
to an increase in the number of activated plaque-associated microglia
that were heterogeneous in their phenotype and were positive for either
Iba1 or both Iba1 and MHCII and this phenotypic diversity arose from
the IL-1β-stimulated recruitment of blood-borne leukocytes into the
brain [226]. Similarly, in another study conducted by Chakrabarty
et al. [227], in which the pro-inflammatory cytokine IL-6 was over-
expressed in the brain of murine models of AD using an adenoviral
vector, it was found that amyloid deposition was attenuated in these
animals. IL-6 expression resulted in a dramatic increase in gliogene-
sis that was associated with enhanced microglial phagocytosis of Aβ,
without affecting APP expression or processing [227]. From these
studies we can conclude that while inflammation has been shown to
be detrimental to the brain, some components of this system may be
involved in amelioration of AD-related pathology.
In studies in transgenic mouse models of AD, TNFα6 released by
microglia in response to Aβ was triggered by an interaction of CD40
with CD40L or by TLR4 engagement [228] [229]. Besides the pro-
duction of inflammatory mediators due to binding of Aβ to various
microglia receptors, Aβ has been shown to be cleared by microglia in
vitro through receptor-mediated phagocytosis and degradation [197] as
described in the next section. In some other studies in animal model of
AD the transient depletion of microglia that have acquired a dysfunc-
tional phenotype has no impact on Aβ burden [230]. Microglial im-
pairment might paradoxically be sustained by inflammatory cytokines
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such as TNFα, IL-1, IL-12 and IL-23 [231] [232] [233]. This idea sug-
gests that AD pathology could be accelerated through this negative
feedback loop. Therefore, the idea of neuroinflammation in AD goes
beyond the degree of mere alterations in microglial morphology and
instead it implies changes in the phenotype and function of these cells,
with relevant consequences. Rare structural variants of genes encod-
ing the immune receptors TREM2 [203] [204] [234] [235], CD33 [206]
[236] and CR1 [237], all of which are expressed on microglia and other
myeloid cells, have been found to be associated with a higher risk of
AD. These findings support the concept of altered microglial function
in AD.
In particular, TYROBP/DAP12 the gene encoding the TREM2
protein described in the previous chapter 1.3.2, was found to be strongly
associated with the pathophysiology of late onset AD (LOAD) as a key
network regulator [203].
Several rare variants of TREM2 in the heterozygous state have
recently been identified by exome sequencing to increase the risk of
late onset Alzheimer disease (LOAD) [238] [205]. This risk factor is
nothing but negligible. In fact, one particular TREM2 variant, R47H,
though not so frequent in the population, has an effect on individual
risk of developing AD comparable with the apolipoprotein ε4 allele
[205] [204].TREM2 was also found to be up-regulated in microglia of
amyloid precursor protein transgenic mouse models [234]. Moreover,
in post-mortem temporal cortices of AD patients, intense TREM2 im-
munoreactivity was observed in the microglia associated with amyloid
plaques and in neuritic pathology-enriched areas [239].
In addition, in the recent publication of Philip W.Brownjohn and
colleagues [240] about microglia derived from human stem cells, pro-
vides tool for understanding microglial biology. These cells are phe-
notypically and functionally comparable with primary microglia. The
authors studied the consequences of missense mutations of TREM2
protein and they found that mutant TREM2 accumulated in its imma-
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ture form, does not undergo typical proteolysis, and is not trafficked to
the plasma membrane. However, in the absence of plasma membrane
TREM2, microglia differentiate normally, respond to stimulation with
lipopolysaccharide and they are phagocytically competent.
Aβ itself has been shown to have proinflammatory properties: mi-
croglia surrounding Aβ plaques show elevated production of inflam-
matory factors [241]. The inflammatory nature of amyloid has been
recognized as a potential mechanism of disease progression. Inter-
estingly, inflammation can promote accumulation of Aβ by elevating
APP levels and the activity of cleavage enzymes [242].
The literature to date highlights the link between Alzheimer’s dis-
ease and inflammation with a rather defined involvement also by mi-
croglia cells, modulators of the inflammation itself, but what was really
interesting were the results coming out our laboratory.
Indeed in our laboratory it was developed the mouse model AD11
that produces specific antibodies against the mature murine form of
NGF, αD11 [243] [244]. αD11 is a monoclonal antibody, produced
in rat, that has the ability of effectively neutralize NGF both in vivo
[245] [18] and in vitro [246] [245].
The AD11 mouse shows loss of BFCNs and presents a form of
neurodegeneration very similar to AD with amyloid plaques derived
from the endogenous APP gene, hyperphosphorilated tau, NFTs, loss
in synaptic plasticity and memory [17] [247] [248]. The AD11 mice
display a comprehensive neurodegeneration that is reminiscent of the
sporadic forms of AD. In our laboratory it was also demonstrated
changes in global gene expression, these were assessed by microarray
mRNA analysis plus RT-PCR validation, and surprisingly, interest-
ing differences could be detected already at P30 mice, when no overt
pathology is present [20].
Moreover, the most significant differentially regulated mRNAs clus-
ter in three families: Wnt signaling, synaptic neurotransmission and
inflammation/immune response.
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Due to these evidences, it was crucial for me trying to understand
if in addition to inflammation response, microglia in this mouse model
was damaged in the early stages as well and whether these alterations
were caused by neurotrophin deprivation or not, as it was important
to understand the role played by the NGF neurotrophin on microglia
neuroinflammation to understand if NGF could somehow aggravate or
improve the inflammation activated by Aβ.
But before start to describe the results of this thesis, it is important
to focus on the other microglia activities as microglia’s Aβ clearance
and the relationship between microglia and neurotrophins.
2.1.1 Clearance of toxic peptides: Beneficial or Detrimental
role of Microglia
In this chapter I will describe the different types of mechanisms used
by microglia to clear Aβ peptides and how different microglia inflam-
matory phenotype can modify its activities, thus making the role of
microglia not always clearly protective. The beneficial or detrimental
microglia role in the Alzheimer’s Disease is still discussed in littera-
ture.
There are two principal mechanisms for removal of Aβ from the
brain: efflux of intact soluble Aβ (sAβ) to the peripheral circulation
and proteolytic degradation of both soluble Aβ and fibrillar forms of
Aβ (fAβ). The efflux of sAβ can occur through a number of differ-
ent routes, including efflux across the blood-brain-barrier (BBB) into
the circulation mediated by LRP1 (low-density lipoprotein receptor-
related protein 1), the bulk flow of interstitial fluid (ISF)/cerebrospinal
fluid (CSF) into the lymphatic system and transport via the P- glyco-
protein (PgP) efflux pump across the BBB. The efflux of Aβ through
these mechanisms has been postulated to be facilitated or inhibited by
its binding to chaperone proteins, such as ApoE, ApoJ, α2-macroglobulin,
transthyretin and albumin [249] [250] [251] [252]. A growing body of
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studies about Aβ clearance has demonstrated that Aβ interacts with
immune cells through both innate and antibody-mediated adaptive
immune responses.
The endocytosis encompasses three primary mechanisms: phago-
cytosis, receptor-mediated endocytosis and pinocytosis. Phagocytosis
and receptor-mediated endocytosis of Aβ are described in the chap-
ters above 1.3.2, the former involves the uptake of large particles whose
internalization is stimulated through its interaction with cell surface
receptors, engaging the cell’s phagocytic machinery [253] and the sec-
ond, the receptor-mediated endocytosis, is a mechanistically distinct
process, elicited by ligand binding to a receptor on the cell surface,
resulting in the internalization of the receptor and its ligand within
clathrin-coated or uncoated vesicles [254] [255] [256].
The pinocytosis can occur through two separate pathways, mi-
cropinocytosis or macropinocytosis, and it is typically associated with
the uptake of solutes from the extracellular medium as described in
the previously chapters 1.3.2.
The mechanism by which soluble or small oligomeric forms of Aβ
are removed from the environment, was well demonstrated by Man-
drekar et al in 2009 [257].
It was demonstrated that macropinocytic uptake of sAβ and its
subsequent proteolytic degradation represents a significant mechanism
mediating Aβ clearance from the extracellular milieu. Although in-
ternalization of the soluble peptide is not limited to microglia, but
these cells are the most efficient in the endocytosis of the peptide in
vitro. Microglia internalize sAβ from the extracellular milieu through
a nonsaturable, fluid phase macropinocytic mechanism that is distinct
from phagocytosis and receptor-mediated endocytosis both in vitro
and in vivo. The uptake of sAβ is dependent on both actin and tubu-
lin dynamics and it does not involve clathrin assembly, coated vesicles
or membrane cholesterol. Upon internalization, fluorescently labeled
sAβ colocalizes to pinocytic vesicles. Microglia rapidly traffic these sol-
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uble peptides into late endolysosomal compartments where they are
subject to degradation. Additionally, it was demonstrated that the
uptake of sAβ and fAβ occurs largely through distinct mechanisms
and upon internalization the peptides are segregated into separate
subcellular vesicular compartments. Remarkably, it was found that
upon proteolytic degradation of fluorescently labeled sAβ, the fluo-
rescent chromophore is retained by the microglial cell. These studies
identify an important mechanism through which microglial cells par-
ticipate in the maintenance of Aβ homeostasis, through their capacity
to constitutively clear sAβ peptides from the brain [257].
Engulfment of fAβ by microglia through receptor-mediated phago-
cytosis and its targeting to the endosome lysosomal pathway have been
investigated in detail [217] [218] [261] [262]. Microglia are able to en-
gulf and phagocyte fAβ readily; the question of whether fAβ can be
degraded intracellularly remains controversial. Early studies showed
that primary mouse microglia release fAβ after they have internal-
ized it [263]. Paresce et al., found that microglia retain fAβ for a
period of weeks without degrading the peptides [264]. A subsequent
study conducted by Majumdar et al., suggested that microglia have
to be activated to enhance their ability to degrade fAβ, as microglia
in a nonactivated state were unable to degrade fAβ. However, stimu-
lating microglia with macrophage colony-stimulating factor (M-CSF)
enabled them to degrade fAβ efficiently through acidification of lyso-
somes [265]. Microglia directly interact with and ingest fAβ via an
ensemble of cell surface receptors, including pattern recognition re-
ceptors (PRRs). PRRs, and most prominently the Toll like receptors
(TLRs), are commonly used by the innate immune system to iden-
tify pathogen-associated molecular patterns (PAMPs) of bacteria and
viruses. The cell surface receptor complex of fAβ (SR-A), the class B
scavenger receptors CD36 consists of class A scavenger receptor α6β1
integrin, CD14, CD47 and TLR2, TLR4, TLR6 and TLR9 [266] [262]
[267] [268]. Upon binding of fAβ, the receptor ensemble initiates the
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activation of intracellular signaling cascades leading to the induction
of phagocytic activity by microglia. SRs were the first receptors re-
ported to be involved in fAβ uptake. Paresce et al., demonstrated
that microglial uptake of fAβ microaggregates was reduced by com-
petitive ligands for SRs [262]. A study conducted by Hickman et al.
reported that the microglial mRNA levels of SR-A, CD36 and RAGE
were progressively and significantly reduced as mice aged [269]. This
suggests that the advance of AD pathogenesis may result from the
decreased ability of microglia to clear Aβ. TLRs and their coactivator
CD14 were shown to stimulate the phagocytosis of fAβ. Activation of
TLRs (TLR2, TLR4 or TLR9) with their specific ligands significantly
enhanced the uptake of fAβ by clonal BV-2 microglial and primary mi-
croglia. However, microglia carrying defective TLR4 were less efficient
than wild-type microglia in their ability to take up fAβ after being
stimulated by lipopolysaccharide (LPS). The results suggest that TLR
signaling stimulates microglial phagocytosis of fAβ. Interestingly, fAβ
itself activates microglia and induces their phagocytic activity through
TLR signaling [270] [266] [267]. Blocking TLRs signaling by interfer-
ing with receptor-ligand interaction or their downstream effectors also
reduced fAβ - induced phagocytosis and signaling [270] [266]. Mi-
croglia deficient in TLR2, TLR4 or their coreceptor CD14 failed to
induce phagocytosis in response to fAβ stimulation [267]. These re-
sults highlight the key function of these PRRs in fAβ uptake and their
stimulation of phagocytosis. Moreover, this process is thought to be
part of the inflammatory reaction in Alzheimer’s disease, the binding
of Aβ with CD36, TLR4, and TLR6 results in activation of microglia,
which start to produce proinflammatory cytokines and chemokines as
shown in figure 1.21.
As said one way to clear Aβ is via phagocytosis and degradation
by resident CNS immune cells, such as microglia [114].
This particular clearance pathway shows microglia not only as the
primary source of inflammatory factors, but also as a crucial element
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Figure 1.21: Activation of microglia by Amyloid-β: Aβ aggregates
(oligomers) act on several Toll-like receptors on the microglial surface,
triggering reactions of the innate immune system, including produc-
tion of pro-inflammatory cytokines and chemokines. Aβ oligomers are
internalised by microglia, aided by SCARA1, α6β1 integrins, CD36,
and CD47 [171].
for removal of harmful material in the CNS [114]. Thus, the failure of
microglia to carry out homeostatic functions possibly underscores one
mechanism of increased Aβ accumulation during disease.
It was demonstrated how the different microglia inflammatory phe-
notype change microglia ability to phagocyte Aβ peptides: for ex-
ample, in vitro treatment of microglia with the pro M1 activator
lipopolysaccharide inhibited microglial phagocytosis of Aβ [270]. Other
proinflammatory cytokines, such as IFNγ and TNFα not only inhib-
ited uptake of Aβ, but also prevented internalized Aβ degradation
[271]. This demonstrates that M1 microglia might be less able to
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properly take up and degrade Aβ. While M1 microglia appear to
be impaired in their ability to remove Aβ, M2 microglia have been
demonstrated to be efficient phagocytes. Treatment with the pro M2
activating cytokine IL-4 can effectively block lipopolysaccharide in-
duced inhibition of Aβ phagocytosis [270] and similar data have been
obtained using IL-10 [270]. This effect also extends to degradation of
the internalized Aβ. These studies showing that inflammation limits
the phagocytic potential of microglia were performed in vitro [270],
but they have been extended in vivo. In the 6-month old APP/PS1
Alzheimer’s disease mouse model Jimenez et al. [272] observed that
when Aβ begins to accumulate there were YM1+ cells present in the
CNS. However, by 18 months of age YM1 mRNA levels decreased
and there was a massive upregulation in inflammatory factors, sug-
gesting a switch from M2 to M1 as pathology worsened [272]. This
is consistent with the idea that microglia become less responsive to
M2 induction signals as they age, perhaps due to an age-associated
decrease in IL-4R levels. Correspondingly, in older, non-diseased mice
there is downregulation of receptors associated with Aβ engulfment,
such as scavenger receptor A, the Aβ degradation enzymes neprilysin
(Nep), insulin degrading enzyme (IDE), and matrix metallopeptidase
9 (MMP-9) [269]. These observations suggest that the Aβ induced
inflammatory environment, combined with age-associated effects on
microglia, leads to a situation where M1 cells predominate and mi-
croglia lose the ability to switch phenotypes and mitigate damage.
Several groups have utilized animal models of Alzheimer’s disease to
demonstrate that altering microglial activation state can be beneficial.
It was also demonstrated that IFNγ and TNFα not only have toxic
effects on neurons but they also reduce levels of insulin degrading en-
zyme, a key Aβ degrading protease. This may be a secondary mecha-
nism through which inflammation could increase amyloid deposition.
Furthermore, both TNFα and INFγ have been shown to increase the
production of Aβ from APP expressing cortical neurons as well as
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impair the ability of microglial cells to degrade Aβ [214].
The generation of mouse models lacking inflammatory signaling
elements has provided insight into the role of inflammation in AD
pathogenesis and Aβ clearance in vivo. AD transgenic mouse models
lacking expression of either the IFNγ receptor type 1 or TNF type 1
receptor display significant decreases in amyloid deposition as well as
microglial activation [273] [274]. Deletion of TNF type 1 receptor also
alleviated Aβ-associated cognitive deficits [275]. However, it cannot
be concluded that inhibition of cytokine signaling promoted microglial
clearance of Aβ in the animal models since both these studies docu-
mented decreases in beta-site APP-cleaving enzyme 1 activity as well.
Since the deletion of these receptors is global it is difficult to assess
their specific contribution in the inflammatory response and clearance
of Aβ in microglia [275] [276].
The emerging role of microglia activation in Alzheimer’s disease
pathogenesis makes these cells a legitimate therapeutic target. How-
ever, depending on the circumstances, microglia activation can have
both beneficial and detrimental effects.
As discussed above, the phagocytic activity of microglia is atten-
uated by proinflammatory cytokines [270], indicating that microglia
committed to an inflammatory response may have a lower phagocy-
totic capacity. In studies with anti-inflammatory drugs, suppression
of the inflammatory response by microglia attenuates symptoms in a
mouse model of Alzheimer’s disease [51].
On the other hand, Schenk et al., reported that active immuniza-
tion to Aβ in a mouse model of AD prevented plaque formation in
younger animals and reduced the plaque burden and associated neu-
ropathy in animals with established plaque pathology [277]. Intro-
duction of anti-Aβ antibodies directly into the brain or peripherally
resulted in a robust phagocytic response of microglia and consequently
the dissolution of Aβ deposition in the brain [278] [279]. These data
argue that the uptake and degradation of Aβ by microglia were a re-
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sult of the Aβ-antibody complex interaction with Fc receptors (FcR)
which stimulated the phagocytic uptake of Aβ.
However, the role of endogenous anti-Aβ antibodies in AD patho-
genesis remains unclear. Indeed, the relative levels of anti-Aβ antibod-
ies in AD patients and healthy individuals are highly variable. The
complement system has also been reported to be involved Aβ clear-
ance [280] [281]. Fibrillar Aβ is a strong stimulator of the complement
system and can activate the classical (antibody-dependent) pathway
by binding Clq and the alternative (antibody- independent) pathway
by binding C3b [282] [283] [284] [280] [285]. Upon opsonization of
Aβ by complement, microglia elicited more aggressive phagocytosis
via complement receptors (1.5-fold increase over fAβ alone) [286] [281]
[287]. Interestingly, the association of the complement component C1q
with Aβ inhibited microglial phagocytosis [288]. Thus, C1q may have
opposing effects on ingestion of Aβ via the SR- and FcR-mediated
pathways, inhibiting naked Aβ uptake and enhancing the Aβ immune
complex uptake. The study conducted by Maier et al. demonstrated
that complement C3 deficiency in APP mice resulted in elevated cere-
bral Aβ levels and amyloid plaque burden. The authors also noticed
that the activation status of microglia was switched from the classical
activation M1 state to the alternative activation M2 state, suggest-
ing the important role of complement system in Aβ clearance and
microglia activation [289].
Nevertheless, the role of microglia in AD is not clearly established.
There are studies indicating that microglia promote disease, whereas
other studies indicate that they are protective. In vitro data demon-
strate that activated microglia can cause neuronal damage. When
microglia or monocytes are incubated with neurons in culture [290],
or with organotypic cultures of rat brains [291], a significant increase in
the ratio of dead to live neurons was detected in cultures containing
Aβ-stimulated monocytes or microglia compared with cultures con-
taining monocytes or microglia stimulated with control peptides. In
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some studies, the presence of microglia was required for Aβ-associated
neuronal damage to occur [290]. When microglia were not included in
the culture, Aβ alone had no significant effects on neuronal survival
[290]: these data are crucial to understand the central role of microglia
in Alzheimer’s Disease damages progression. These studies indicate
that microglia recruited to senile plaques might play a part in Aβ-
induced neuronal damage in AD. By contrast, there is also increasing
in vivo evidence indicating that accumulation of microglia in AD might
be protective and promote Aβ clearance. It was found that accumu-
lation of blood-derived microglia before formation of visible Aβ de-
posits promotes Aβ clearance. Indeed, abolishing such accumulation,
as it occurs in mice model deficient in the chemokine receptor CCR2,
leads to development of early visible Aβ deposits, specifically around
blood vessels, and it has been associated with increased mortality in
these mice, indicating that CCR2 function on circulating monocytes
or microglia is required for prevention or clearance of perivascular Aβ
deposits [292]. In support of this protective role for microglia, it was
also found that bone-marrow-derived microglia have an important role
in restricting plaque formation in irradiated mice also by promoting
phagocytosis and clearance of Aβ [292]. This concept was further sup-
ported when IL-1β was overexpressed in the brain of PS1-APP mice.
These mice had dramatical induced CCL2 expression in their brains,
increased microglia accumulation and activation and reduced AD-like
pathology [226]. Similarly, enhancing microglial accumulation by in-
creasing mononuclear phagocyte recruitment from the blood into the
brain, as in AD mice deficient in peripheral mononuclear phagocyte
transforming growth factor-b signaling, significantly reduced AD-like
pathology [293]. Another approach that showed the importance of
microglia for plaque removal used intraventricular transplantation of
exogenous microglia, which migrate into the parenchyma and increase
the clearance of amyloid plaques [294].
This approach provides a basis for the concept that microglia might
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play different roles at different time points in the progression of AD
pathogenesis. Early microglia accumulation, which begins before for-
mation of visible Aβ deposits, might be beneficial. Microglia recruited
at early stages of AD phagocytose and clear Aβ and, hence, protect
the brain from the toxic effects of Aβ. As the disease progresses, how-
ever, and with persistent production of pro-inflammatory cytokines
such as TNFα and IL-1β, microglia lose their protective phenotype
and their ability to keep up with Aβ deposition and become dysfunc-
tional and unable to clear all of the Aβ [269], hence promoting plaque
formation. In support of these findings, it was recently shown that
plaque-associated microglia seemed healthy, maintaining their ability
for rapid process and membrane movement, but the plaques continued
to grow despite additional microglia accumulation [295] [296]. The
inability of microglia to phagocytose and clear Aβ in these plaques
might lead to a process called frustrated phagocytosis, which results in
the persistent release of pro-inflammatory enzymes, reactive oxygen
species, cytokines and chemokines [297]. In addition to downregulat-
ing Aβ clearance, these products of activated microglia are neurotoxic
and, hence, promote neuronal degeneration.
Microglia immune activity is restrained by dedicated immune in-
hibitory pathways that suppress unwanted inflammatory responses
and tissue destruction that are often associated with immune activa-
tion [51]. These checkpoint mechanisms include direct inhibitory in-
teractions of microglia with neurons through the receptor-ligand pairs,
soluble molecules present in the CNS (e.g. TGF-β) and intracellular
regulators such as the transcription factor MafB [298] [299] [300] [301].
As discussed before, numerous studies reported conflicting results re-
garding the contribution of systemic immunity, recruited monocytes,
and tissue-resident microglia to AD onset and disease progression.
Some reports show that under such conditions, microglia acquire pro-
inflammatory activity, which has been associated with disease escala-
tion [76] [302] [303] [304].
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Recently single cell genomic technologies enable unbiased charac-
terization of immune cell types and states, transitions from normal to
disease and response to therapies; single-cell analysis can further iden-
tify potential markers, pathways, and regulatory factors, promoting
testable hypotheses to elucidate molecular mechanisms of immune reg-
ulation in AD [305]. [301] Taken together, it is still not clear whether
microglial function in neurodegenerative diseases is beneficial but in-
sufficient, or whether these cells are effective at early disease stages
but lose their efficacy or even become detrimental later on. In partic-
ular, the pathways and molecular mechanisms of microglia activity at
the different stages of AD thereby remain controversial. Hadas Keren-
Shaul and colleagues in their last 2017 paper combine massively paral-
lel single-cell analysis with chromatin profiling, single-molecule FISH
(smFISH), immunohistochemistry, genetic perturbation, and compu-
tational modeling to comprehensively characterize de novo the in-
volvement of the immune system in AD progression. Using a mouse
model of AD that expresses five human familial AD gene mutations
(5XFAD), they uncover a disease-associated microglia (DAM) subtype
[8]. Their results also depict the pathways activated in DAM, which
have been associated with known AD risk factors, but not specifically
attributed to microglia. Using sub-tissue-focused single-cell RNA-seq
and smFISH, they identified the spatial location of DAM in proximity
to Aβ plaques. Immunohistochemical staining showed an increased
number of microglia that are positively stained for intracellular Aβ
particles and DAM-markers in both 5XFAD mice and in human AD
postmortem brains. From comparison of triggering receptor expressed
on myeloid cells 2 (TREM2)/5XFAD with TREM2+/+5XFAD mice
revealed that initial DAM activation, that includes upregulation of Ty-
robp (TREM2 receptor) Apoe and downregulation of microglia check-
point genes (e.g., Cx3cr1), is TREM2-independent but full activation
of the DAM program including phagocytic and lipid metabolism ac-
tivity is a consequential event that is TREM2-dependent, see figure
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1.22.
Overall, these study identifies a potential protective microglia type
associated with neurodegeneration and outlines a general framework
for studying the involvement of the immune system in AD pathology.
Figure 1.22: DAM are Regulated through a Two-Step Activation
Mechanism Schematic illustration showing microglia switching from
homeostatic to stage 1 DAM (Trem2-independent) and stage 2 DAM
(Trem2-dependent) following signals such as those associated with AD
pathology, aging, and ALS pathology. Key genes involved in each
stage are shown below each condition. Arrows indicate up (red) or
down (green) regulation of the gene in the specific stage [8].
3 Microglia and Neurotrophins
In the previous chapters the physiological functions of microglia were
discussed with special attention to its role during pathological condi-
tions which can be protective or toxic because of their pro-inflammatory
iper-activation.
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As for the potential protective role played by microglia, it is im-
portant to describe their capability to produce neurotrophins, which
are known to have protective (beneficial) and neurotrophic effects on
neurons.
Little is known about microglia and neurotrophins. In particular,
it is not well established which functions neurotrophins may have on
microglia activity.
Indeed, it exists a sort of neurotrophin theoretical paradigm which
states that each neurotrophin is neuroprotective on its corresponding
set of target neurons. The correspondence between neurotrophin and
its target neurons determines the neuroprotective spectrum of a target
neuron. For NGF this paradigm claims that its target cells are basal
forebrain cholinergic neurons [15].
The neurotrophins are a family of protein factors composed of at
least five structurally related members: nerve growth factor (NGF)
[306] [307] [308], brain-derived neurotrophic factor (BDNF) [309] [310],
neurotrophin-3 (NT-3) [311] [312] [313] [314] [315], neurotrophin-4/5
(NT-4/5) [316] [317], and NT-6 [318]. These proteins regulate the neu-
ronal function and also support the survival, enhancing the growth
of various types of neurons in both the peripheral nervous system
(PNS) and the central nervous system [319] [310] [320] [321] [322].
Neurotrophins participate in multiple developmental processes rang-
ing from survival of neurons [323] [324] to proliferation of oligodendro-
cyte precursors [325] and axon growth [326]. Microglia are sources of
trophic factors known to support development and normal function of
CNS cells and microglia are responsive to neurotrophins: brain-derived
neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) induce pro-
liferation and phagocytic activity of microglia in vitro [327] [9].
Secretion of nerve growth factor (NGF) from activated brain macrophages
has also been reported [328]. Some studies have indicated that mi-
croglial conditioned medium promotes survival and development of
mesencephalic neurons and stimulates myelination in vitro [329]. Elk-
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abes and colleagues in 1996 were the pioneers that investigated the role
of microglia and neurtrophins in vivo and in vitro [9]. They focused
on these trophic factors because their involvement in the development
and growth of the CNS had been well documented.
The finding that removal of neurotrophins from animals by specific
antibody or by gene knock out results in a variety of nervous system
abnormalities [330] [331] [332] [333] [334] [335] [18] [17] also supports
the claim that neurotrophins are functionally prerequisite factors in
the nervous system. Neurotrophins such as NGF, BDNF, and NT-3
were originally shown to be produced in target neurons or tissues in
both the PNS and the CNS [336] [311] [315], but later they were re-
ported to be produced in glial cells as well. Astrocytes have been found
to express mRNAs and proteins of the neurotrophin family, including
NGF [337] [338], BDNF [339], NT-3 [340], and NT-4/5 [341] in vitro,
and to express NGF [342] [343] [344] in vivo. Microglia have been also
found to have the ability to produce NGF in vitro [345] [328], and
more recently they have been reported to produce BDNF and NT-3
both in vitro and in vivo [9]. These findings further suggest that the
neurotrophins produced by glial cells act on glial cells in an autocrine
and/or paracrine fashion in addition to neurons. However, informa-
tion on the significance of neurotrophins in the regulation of glial func-
tion has been quite limited. In 1998 Nakajima and colleagues, for the
first time, tested the hypothesis that neurotrophins regulate microglial
function in the CNS, demonstrating biochemically the ability of four
different neurotrophins to regulate secretory products and character-
istic enzyme activities of cultured microglia [346]. They demonstrated
how NGF, BDNF, NT-3 and NT-4 does not influence microglia pro-
liferation but enhance, in dose dependent manner, the PGn (Plas-
minoge) and PA (Plasminogen Activator) release, while decreasing
the amount of NO (Nitric oxide). The effect shown by BDNF was
stronger than the other neurotrophins. It was also demonstrated in
colture microglia the trkA, trkB, trkC and p75NTR receptors mRNA
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and protein expression. They demonstrate the Trks activity mediated
by their phosphorilation. They tested also p75NTR activity, cultured
microglia were treated with each neurotrophin (200 ng/ml) for various
time and then analyzed for NF-kappaB and IkB proteins by West-
ern blotting. The exposure of microglia to each neurotrophin led to
the time-dependent degradation of both IkappaBα and IkappaBβ but
no change was observed in total amount of NF-kappaB (p65) at any
point. They have examined immunocytochemically the localization
of NF-kappaB by using an antibody to p65 subunit of NF-kappaB.
In the non-stimulated microglia, NF-kappaB was found mainly in the
cytoplasm. However, when microglia were treated with NGF (200
ng/ml) for 2 hours, p65 was found to be translocated to the nucleus
in many cells. BDNF and NT-3 were also effective with similar degree
on the translocation of p65 to nucleus as far as microglia are stimu-
lated with a concentration of 200 ng/ml. The degradation of IkappaB
and nuclear translocation of NF-kappaB by relatively high dose of
neurotrophins strongly suggest the involvement of p75NTR in the mi-
croglial responses [346]. The same year, Hesse and colleagues demon-
strated that the cytokines interleukin-1β and tumor necrosis factor-α
synergistically stimulate microglial NGF transcription and protein re-
lease. Moreover, exposure of microglial cells to complement factor
C3a induces NGF expression. To assess the role of the transcription
factor NF-kappaB in inflammatory mediator-induced microglial NGF
expression, the effect of the NF-kappaB inhibitor pyrrolidine dithio-
carbamate (PDTC) was analyzed. In the presence of PDTC, a dose-
dependent inhibition of cytokine-activated NGF expression occurred.
In contrast, the C3a-dependent stimulation of NGF synthesis was not
influenced by PDTC. In addition, microglial neurotoxicity-mediating
beta-amyloid peptides Aβ(1-40) and Aβ(1-42) failed to alter NGF syn-
thesis, whereas Aβ(25-35) specifically induced NF-kappaB-dependent
microglial NGF expression. They concluded that inflammatory sig-
nals (cytokines and complement factors), as well as Aβ(25-35), are
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potent stimulators of human microglial NGF synthesis involving NF-
kappaB-dependent and independent mechanisms. Microglial secretion
of neurotrophins appears to be involved in early processes of neuronal
regeneration [10].
Along the same lines of interests, Jose Maria Frade and Yves-Alain
Barde, published very interesting results about the effect of NGF se-
crete microglia, demonstrating a new particular role carried out by
NGF. In fact it was demonstrated that NGF can also cause cell death
during development by activating the neurotrophin receptor p75NTR;
they also identified microglial cells as the source of NGF as a killing
agent in the developing eye: when the retina was separated from sur-
rounding tissue before the colonization of microglial cells, no NGF can
be detected and cell death is dramatically reduced, an the effect is re-
stored by the addition of microglia cells, but these effects was blocked
by NGF antibodies. These results indicate an active role form mi-
croglia in neuronal death during the developement, mediated by NGF
[147].
Around 2001 Nakajima and collegues demonstrated microglia neu-
rotrophin secretion. They observed that BDNF is constitutively se-
crete while NGF only after LPS stimulation [347].
Later in two different microglia cell lines, BV2 and N9, neurotrophins
mitotic activity was tested. The authors demonstrated that BV2 was
more sensible to NGF than N9 line. They also demonstrated that NGF
enhances cell proliferation in cell lines on the contrary on primary mi-
croglia, while NT-3 and NT-4 had no effect on cell proliferation. The
response of these cells to neurotrophins was blocked by K252a, a ty-
rosine kinase inhibitor, suggesting that actions of neurotrophins were
mediated by high-affinity tyrosine kinase receptors (Trk)[348].
It was also tested whether NGF was able to influence microglial
motility. It was found that NGF induced chemotaxis of microglial cells
through the activation of TrkA receptor. In addition, NGF chemotac-
tic activity was increased in the presence of low concentrations (< or
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=0.2 ng/ml) of transforming growth factor-beta (TGFβ), which at
this concentration showed chemotactic activity per se. On the con-
trary, NGF-induced microglial migration was reduced in the presence
of chemokinetic concentration of TGFβ (> or =2 ng/ml). These obser-
vations suggest that both NGF and TGF-beta contribute to microglial
recruitment [12].
More recently a milestone paper was published by Parkhurst and
colleagues on the role of microglia BDNF during brain development.
They studied the physiological roles and function of microglia in brain
plasticity using mice expressing tamoxifen-inducible Cre recombinase,
finding that microglia could be specifically depleted from the brain
upon diphtheria toxin administration. Mice depleted of microglia show
deficits in multiple learning tasks and a significant reduction in motor
learning-dependent synapse formation. Furthermore, Cre-dependent
removal of brain-derived neurotrophic factor (BDNF) from microglia
largely recapitulated the effects of microglia depletion. Microglial
BDNF increases neuronal TrkB phosphorylation, a key mediator of
synaptic plasticity. Together, these findings reveal important physi-
ological functions of microglia in learning and memory by promoting
learning-related synapse formation through BDNF signaling [1].
In the end it’s quite clear how the neurotrophins are really impor-
tant modulators of microglia functions but more in general how they
are important to modulate brain physiology through microglia activa-
tion. However, it is not so well established the direct and accurate role
of NGF on microglia and the potential activity conducted by NGF on
these cells, and so I decided to investigate more.
Chapter 2
Results
1 Microglia phenotype in AD11 mice
As described in the previous chapter telling about Alzheimer’s Disease,
in our laboratory the mouse model AD11 was developed [17] [18]. This
model produces specific antibodies against the mature murine form of
NGF, αD11 [243] [244].
The AD11 mouse shows a progressive comprehensive neurodegen-
eration that eventually shows all major hallmarks of AD neurodegen-
eration, massive and widespread neuronal loss, amyloid deposits (from
the endogenous APP gene), and extensive neurofibrillary pathology.
Moreover, these mice exhibited a severe cholinergic deficit in the basal
forebrain and a behavioral impairment in retention and transfer of
spatial memory tasks as shown in figure 2.1 [17].
The mechanism of this progressive neurodegeneration have been
ascribed to an experimentally induced imbalance between proNGF
and NGF [21] [19], but the cellular basis of the progressive neurode-
generation induced by anti NGF antibodies has remained uncertain.
In order to detect the earliest changes in the progressive neurode-
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generation, following the postnatal onset of the anti NGF antibody
expression in the brain, was carried out at 1 month of age, well be-
fore any other overt phenotypic change, showing a number of mRNA
changes.
Figure 2.1: Alzheimer’s Disease progression in Anti-NGF mice.
Among the most significant mRNA expression changes observed in
the hippocampus and cortex of P30 AD11 mice are mRNAs cluster
of three families: Wnt signaling, synaptic neurotransmission and in-
flammation/immune response [20]. Quantitatively speaking the most
differentially expressed mRNA are involved in inflammation and this
is consistent with what is seen in genetic studies for AD [349].
On this perspective the neurodegenerative phenotype in AD11
mice is more complex compared to what one would on the basis of
the simple direct NGF/cholinergic connection. Though the neurode-
generation must be due to the NGF deprivation, since delivery of NGF
to the brain induces a complete reversion of the phenotype [350] [351].
The specific mode of neutralization of NGF might be of notice since
the Fc constant region of the antibody could entail additional effects
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as opposed to a full gene knock out approach. On the other hand, the
mere presence of an antibody in the brain is not sufficient to induce the
neurodegeneration since other neuroantibody transgenic mice [352] do
not develop the same phenotype.
These results suggest us several open questions in AD11 biology,
one of them is what cell type mediates the phenotype. So I started
to investigate if microglial cells, the inflammatory mediators, were in-
volved in the AD-like phenotype of this peculiar mouse model, focus-
ing in the presympthomatic and early sympthomatic phases (1 and
6 months) proposing a microglial impairment due to NGF depriva-
tion. As at one month changes in the AD11 transcriptome are already
detected, I analyzed microglia starting from that time point. The 6
months’ time point represents the beginning of the Aβ accumulation
and behavioral impairment without the neuronal cell loss associated
in AD with the proinflammatory-activated (potentially neurotoxic)
microglial phenotype. So it is in this time frame that changes of
the homeostasis of microglia might be able to induce the patholog-
ical framework of AD, should be detected.
The experiments for AD11 mice were also performed using two
groups of controls: wild-type mice (WT) and the corresponding single
transgenic controls (VH), homozygous for the anti NGF αD11 heavy
chain, expressing only the VH-αD11 heavy chain of the chimeric an-
tibody, αD11, that detect and neutralize NGF. The VH-αD11 heavy
chain does not bind NGF.
The microglial phenotype in AD11 mice was evaluated through
a classical morphological approach but with specific parameters di-
rected towards a more subtler evaluation of phenotypic changes in mi-
croglia. The parameters were valuated in both entorhinal cortex and
molecular layer of hippocampus, at AD11 one month age (the earliest
pre-symptomatic phase) and at 6 months (the beginning of the Aβ ac-
cumulation and behavioral impairment)(Fig.2.2A-B) and Images from
AD11, VH and WT mice were acquired by confocal laser scanning mi-
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croscope and analized with Bitplane’s software Imaris (Fig.2.2D).
We analyzed entorhinal cortex and molecular layer of hippocampus
due to their related impairment in AD in general and in AD11 mice
specifically. Microglia cells were evaluated measuring the shape and
length of the cell processes (filaments) and some other parameters were
analized, i.e. filament length per cell, number of branching points per
cell, volume of the entire slice, number of cells per slice.
Figure 2.2: Stacks obtained from a WT mice, showing extensive Iba1
positive ramifications all over the hippocampus (A) and the cortex (B).
Selection of the ROI in the hippocampus (C). Inside the IHC: Image
taken with Imaris (Zurich, Switzerland). Blue spheres are microglial
nuclei. Green filaments are the microglial processes (D).
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Figure 2.3: These histograms show values on 1 month old animals
(enthorinal cortex). Bars are representative of the mean ± S.E.D.
The results shown in Fig.2.3 describe a significant decrease in
branching length per cell, branching complexity and branching den-
sity of the microglia in AD11 entorhinal cortex compared to controls,
indicating that at this early stage of the neurodegeneration there is
already a decrease of the microglial branching. Thus a subpathologi-
cal impairment can be already observed at this age. VH mice seem to
show a more subtler decrease in branching complexity that their AD11
counterparts, while also in the Branching length per cell parameters
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shows a significant, though barely, increase.
The results of the hippocampus analysis in Fig.2.4,
Figure 2.4: These histograms show values on 1 month old animals
(hippocampus). Bars are representative of the mean ± S.E.D.
show less pathological changes than in the enthorinal cortex, since
only a decrease in branching density and complexity but not branch-
ing length per cell can be observed. Interestingly, there is also a
slightly significant decrease in cell density in AD11 with respect to
controls, as yet another sign of microglia subtle impairment. In many
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of the parameters VH show an intermediate phenotype between full on
AD11 and WT with decreased branching density and complexity. At
6 months of age, it was shown the same tendency towards a decreased
branching in the entorhinal cortex (Fig.2.5),
Figure 2.5: These histograms show values on 6 month old animals
(enthorinal cortex). Bars are representative of the mean ± S.E.D.
where AD11 mice demonstrate a reduced branching length per cell
and branching density. The same result can be observed in the hip-
pocampus (Fig.2.6), where branching length per cell, branching com-
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Figure 2.6: These histograms show values on 6 month old ani-
mals(hippocampus). Bars are representative of the mean ± S.E.D.
plexity and branching density are all decreased compared to the WT or
VH. Yet no difference in cell density was detected. At 6 months there
is barely a difference between VH and WT. The microglial impairment
evaluated through morphological parameters is therefore present both
at 1 and 6 months of age.
Given that microglia ad the inflammatory homeostasis of hippocam-
pus and cortex are affected in anti NGF AD11 mice very early on, as
CHAPTER 2. RESULTS 90
the earliest observed phenotypic deficit, I postulated that microglia
might be a target cell of NGF in the brain and decided to investigate
the role of NGF on microglia.
2 Microglia express NGF receptors in vivo
and in vitro
The first step to validate microglia as NGF target cells was to as-
certain whether they express functional NGF receptors. Experiments
were performed using both primary mouse microglia and the immor-
talized mouse microglial cell line, BV-2 [353]. First, we found by
immunofluorescence and FACS (Fig.2.7 A, B) that primary microglia
and BV-2 cells express both TrkA and p75NTR. In primary microglia
TrkA and p75NTR were expressed respectively by 44.8% and 39.4%
of cells (Fig.2.7 B) .
The data obtained by immunofluorescence and FACS were con-
firmed by western blot (Fig.2.8 C) . To assess the NGF signaling com-
petence of microglial TrkA and p75NTR, cells were grown in serum
free conditions for 16 hours and incubated with 100 ng/ml of mouse
NGF. We found that while the expression of p75NTR and total TrkA
remained constant over time (Fig.2.8 C), NGF determined a signifi-
cant increase of phosphorylated TrkA (pTrkA) in primary microglia,
TrkA exhibited a significant time dependent activation upon treatment
with the neurotrophin (measured as the ratio between phosphorylated
TrkA and the total amount of TrkA (Fig.1C-D; (∗ p≤ 0.05 at 5 min
and ∗ ∗ p≤0.01 at 15 and 30 min). In BV-2 cells the relative levels
of pTrkA remained relatively stable, (Fig.1C-E; p≤0.05). Concerning
the downstream intracellular signaling, the incubation with NGF se-
lectively activated AKT and c-jun (an established proxy for p75NTR
activation) in both cell types (Fig.1C-E, p≤0.05), while the expres-
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Figure 2.7: Primary microglia and BV2 cells express NGF receptors.
(A) Example pictures of NGF receptors staining: TrkA and p75NTR
(green) are shown in these images of confocal Immunofluorescence of
primary microglia and BV-2 cells (red). (B) Flow cytometry plots
shows the over gate cells positive for TrkA and p75NTR receptors
in primary microglia and BV2 cells. (Data are mean ± SD all data
are representative of three independent experiments, ∗ p≤0.05, ∗ ∗
p≤0.01, Student’s T-test)
sion of phosphor-Erk remained unchanged (Fig.1C-E; p≥0.05). Thus,
in cultured microglia NGF activates both TrkA and p75NTR recep-
tors, initiating at least some of the signalling cascade specific to these
receptors.
We then proceeded to assess TrkA and p75NTR expression in adult
ex vivo glial cells. Triple staining was performed to detect the TrkA
receptor distribution in sections of mouse cortex. Experiments showed
colocalization of TrkA and Iba1 both in the cell bodies and branches
of microglial cells (Fig.2.9 A; n=3; 3 experimental replicates) .
On the other hand, astrocytes (GFAP+ cells) showed a sparse
overlapping with the anti-TrkA antibody, MNAC13 (Fig.2.9 B: n=3;
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Figure 2.8: Primary microglia and BV2 cells express NGF receptors
and activate receptor-mediated intracellular signaling after NGF stim-
ulation. (C) The panel shows western blot signalling results for pro-
teins involved in NGF signalling transduction pathways of TrkA, AKT,
Erk and cjun. On the right are shown the histograms quantification
of phosphorylated protein normalized on the total protein level for
primary microglia (D) and BV2 cells (E). (Data are mean ± SD all
data are representative of three independent experiments, ∗ p≤0.05,
∗ ∗ p≤0.01, Student’s T-test)
3 experimental replicates). Ultimately, labeling of the p75 receptor
showed some rare points of colocalization with CD11b+ cells (Fig.2.9
C, n=3/6) while no expression could be detected on astrocyte bodies
or branches (n=3/3 data not shown). Thus, we conclude that both in
vivo and in vitro microglia possess NGF receptors, and - specifically
in cell culture - we could observe normal receptor kinetics in response
to the neurotrophin, indicating that these receptors are indeed active.
.
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Figure 2.9: Expression pattern of NGF receptors in murine brain slices.
(A) The anti-TrkA MAb MNAC13 (red label) stains cortical microglia
iba1 positive cells (green label). Merging areas (yellow label) and
magnification (inset) show that the labeling involves both cytoplasm
and fibers. (B) (middle panels) MNAC13 staining slightly overlapped
with the astrocytic marker GFAP (in green). Below, (C) p-75NTR
(red label) is slightly expressed in CD11b1 microglia (green label)
from cortical sections. Merging areas (yellow label).
3 NGF modulates the expression of genes
involved in pathways of cell motility,
phagocytosis and protein degradation
To gain insight into the downstream effects of NGF signaling in mi-
croglia and on potential functional microglial responses to NGF, mi-
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croarray gene expression profiling was performed on primary microglia
treated with NGF (100 ng/ml) either for 2, 8 or 24 hours. NGF in-
duced global transcriptomic changes throughout the three time points.
At two hours, the majority of differentially expressed genes (DEGs)
were downregulated, while at 24 hours there was a reversal, with a
trend toward upregulation (Fig.2.10 A).
KEGG gene ontology analysis was performed, to cluster the DEGs
into over-represented pathways, thus identifying those primarily mod-
ulated by the incubation with NGF. Interestingly, at 2 hours the ma-
jority of upregulated genes were linked to focal adhesion and extra-
cellular matrix interactions, while downregulated genes were related
to cytoskeleton rearrangement (Fig.2.10 B). At 8 hours, genes of cell
adhesion molecules and of the protein digestion and absorption were
still upregulated (Fig.2.10 B). At 24 hours, the majority of upregulated
genes belonged to the neuro-ligand interaction and to the phagosome
pathways, while downregulated genes belonged to endocytosis, focal
adhesion, adherens junction, cytokine-cytokine receptor interaction,
and chemokine signalling pathways (Fig.2.10 B). Then we focused on
the analysis of specific gene clusters highlighted by the KEGG analy-
sis, such as those involved in actin cytoskeleton regulation, endocytosis
and chemokine signalling. In addition, we analyzed in more detail the
expression of genes involved in protein digestion, neurotrophin sig-
nalling and genes linked to Alzheimer’s disease. For each of these
clusters, we represented the total amount of genes mapped to the spe-
cific KEGG category at each time point (Fig.2.11 A)
and the corresponding heat maps, providing a graphical represen-
tation of the change in expression of the genes over time (Fig.2.11
B). We found that the major changes occur at 24 hours for all clus-
ters. At this time, NGF induced a significant downregulation of rhoA
and rock2, genes involved in actin dynamics [354] [355], while most
genes related to endocytosis and lysosomal activity, such as Gm2a
[356] , were up-regulated. Concerning the neurotrophin signalling and
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Figure 2.10: NGF modulates microglial gene expression. (A) The
bar plot shows the global number of differentially expressed genes,
up-and down-regulated by NGF at 2, 8 and 24 hrs. Gene lists were
selected using two different thresholds: 2.0 fold-change in linear scale
and Limma P-Value≤0.05 (blue for down-regulated and plum for up-
regulated); 4.0 fold-change in linear scale and Limma P-Value≤0.05
(green for down-regulated and red for up-regulated). (B) The horizon-
tal bar plot shows the significantly enriched KEGG terms, following
NGF treatment. Enriched pathways refer to up-regulated genes (right
bars) or down-regulated ones (left bars), at 2, 8 and 24 hrs (green, grey,
light grey bars respectively). The analysis was performed on differen-
tially expressed genes selected by two thresholds: corrected P-Value
(FDR) ≤ 0.05 and 1.0 fold-change in linear scale.
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Figure 2.11: NGF modulates different pathways in microglia in time
dependent manner. (A) The histograms show the adjusted P-Value
(FDR) of selected enriched KEGG pathway at 2, 8 and 24 hrs (green,
grey, light grey bars respectively). Each bar contains the number
of differential genes mapping to each specific pathway. (B) Heatmaps
show the Log2 fold-change ratio of genes mapping to the corresponding
modulated pathways on the top.
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Alzheimer’s disease pathways, we found an upregulation of sort1 and
ApoE, both known as risk factors in Alzheimer’s disease [357] [358].
Finally, we looked at mRNAs involved in the inflammatory response,
whose modulation is a major functional response of microglial cells.
Interestingly, this mRNA class was not significantly represented among
the mRNAs upregulated by NGF at 24 hours. The largest modula-
tion was actually the downregulated expression of cxcl5, ccl12, ccl2.
Overall, these data suggest that NGF might influence the motility,
the phagocytic and protein degradation abilities of microglia, without
activating them in the classical proinflammatory sense. We therefore
looked at these microglial functions in more detail.
4 NGF enhances microglial membrane dy-
namics, but not their cell speed.
The surveillance activity of microglia cells is mediated by the translo-
cation of their cell body towards sites of injury, where chemoattractant
substances are released, and by finer - highly dynamic - movements
of cell membrane and processes, resulting in the extension and retrac-
tion of their branches in response to either physiological or pathological
stimuli [41] [40]. These are accomplished through changes in the struc-
ture of their cytoskeleton. The transcriptome analysis demonstrated
specific changes regarding cytoskeletal related genes. Thus, we asked
whether NGF might induce changes in cell body migration and in the
motility of cell membrane and processes. The chemotactic properties
of NGF specifically on microglial cells are already documented in the
literature [12]. In this work Minghetti and collaborators proved NGF
capable of increasing the migratory ability of microglial cells by acting
on the high affinity TrkA receptor. Our in vitro approach to assess the
effects of NGF on motility - a necessity arisen from transcriptomics
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results - was that of operating time-lapse recordings of NGF-treated
- freely moving - microglial cells. Primary microglia were monitored
for 1h in a culture chamber after treatment. Videos were analyzed by
means of a self-made Python-based script capable of extracting and
quantifying useful features of the microglial motility behavior. This
analysis unveiled that the speed of the cell body of NGF- treated
microglial cells was not significantly different from that of untreated
microglia (Fig. 4B), meaning there was no overall translocation of
the entire cell from one place to another. This result is in line with
the work of De Simone et al. [12]: when they eliminated the chemo-
tactic gradient, they could no longer observe the change in migratory
behavior induced by NGF thus excluding a chemokinetic effect. We
then concentrated on another parameter of cell motility: cell mem-
brane changes. These structural changes occurred on a timescale of
minutes and were evaluated as the difference in cell area between two
consecutive frames (∆A) normalized over the cell perimeter p (∆A/p).
Since this parameter evaluates the change of the cell area, a mea-
surement of its capacity to elongate and retract, this can be thought
of as an in vitro measure of exploratory behavior. We found that the
treatment with NGF induced a significant increase in this exploratory
tendency in microglial cells as in figure 2.12 A, B.
.
5 NGF promotes microglial macropinocy-
tosis but not phagocytosis
Microglia are capable of engulfing material through three different
mechanisms: phagocytosis, receptor-mediated endocytosis and pinocy-
tosis. Phagocytosis is used to internalize large particles [253], while
pinocytosis is typically associated with the uptake of soluble sub-
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Figure 2.12: NGF modulates microglial motility dynamics. (A)
Bright-field image during a time lapse of primary microglia from
CX3CR1-GFP mice. (B) In the panel, it is shown the pattern recogni-
tion from a homemade Python based script that describes (1-3) naive
cells and (4-6) NGF cells. The boxes show in (1, 4) perimeter in
violet and cell center in pink, (2, 5) perimeter difference between 2
consecutive frame, (3, 6) cell speed. The histograms show the plotted
results of these parameters: cell membrane changes and speed (n=29;
data are mean ± SD; all data are representative of three independent
experiments ∗ p≤0.05, Student’s T-test).
stances, such as soluble Aβ peptide [257]. In microglia, protrusions of
the cell membrane are associated with phagocytic activity. We thus
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evaluated whether the NGF-dependent changes in membrane motility
might underlie and reflect changes in engulfing processes. To do so,
we used an in vitro assay - followed by FACS analysis - where pri-
mary microglial cells were incubated with either fluorescent opsonized
latex beads or dextran in the presence or absence of NGF. Beads
are ingested through a phagocytosis process, while dextran through
macropinocytosis [359] and it is possible to discern these processes
thanks to known inhibitors and activators of the cellular mechanisms
behind these different engulfment processes: for the phagocytosis of
big particles (beads) IFN-γ was used as positive control of activation
of the process in microglia [360], while PMA and Rac-cdc42 activator
I as promoters of macropinocytosis of dextran [359] [361]. NGF was
found not to increase the number of latex beads internalized by mi-
croglia (Fig.2.13 A) . As regards macropinocytosis, NGF increased the
internalization of dextran to a degree comparable to the established
activators of the process, PMA and Rac-cdc42 activator-I (Fig.2.13
B). As expected, amiloride and cytochalasinD inhibited the process
(Fig.2.13 B). Thus, we conclude that NGF is able to selectively upreg-
ulate macropinocytosis while microglial phagocytosis of bigger parti-
cles, such as opsonized beads, is not affected by this neurotrophin.
6 NGF activates microglia currents and
modulates glutamatergic neurotransmis-
sion by acting on microglial cells
An ex vivo correlate to microglial behavior in response to NGF was ob-
tained by performing patch clamp recordings from microglia in acute
brain slices. Our data reveal that NGF triggers an outward current
(Fig.2.14 A). To study changes in this outward NGF-induced current,
we repetitively clamped the membrane from a holding potential of -20
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Figure 2.13: NGF enhances macropinocytosis of dextran but not
phagocytosis of beads. Flow cytometry (580-650nm absorption) to
count the number of cells that phagocyte the differents debries (A)
Phagocytosis of beads: Primary microglia from CX3CR1-GFP mice
were incubated with 6µm beads and 10 ng/ml IFNγ, 100 ng/ml NGF,
100 nM PMA and 1 µg/ml Rho/Rac/Cdc42 activator I for 3 hrs. (B)
Macropinocytosis of dextran: Primary microglia from CX3CR1-GFP
mice were incubated with 2.5 mg/ml Dextran and 10 ng/ml IFNγ,
50 µM Amiloride, 5µg/ml Cytochalasin-D, 100 ng/ml NGF, 100 nM
PMA and 1µg/ml Rho/Rac/Cdc42 activator I for 3 hrs. (mean ± SD,
∗ p≤0.05, Student’s T-test).
mV to a series of hyperpolarizing and depolarizing voltage steps before
and after the application of NGF (Figure2.14 B, left inset). The cur-
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Figure 2.14: NGF affects microglial currents thereby enhancing excita-
tory neurotransmission. (A) Time plot of the mean current amplitude
induced by NGF application recorded from microglial cells (n517). (B)
Left, current-voltage relationship of the NGF-induced current by ap-
plication of NGF (20 γ) in a microglial cell from acute cortical slice
of CX3CR11/GFP mouse before (black curve) and after 5 (light gray
curve) and 10 min (red curve) NGF application. Right, NGF induces
an outward rectifying current with reversal potential at about 15 mV
at a holding potential 5220 mV (results obtained by subtracting the
current before and after the NGF application).
rentvoltage clamp curve of the response to NGF was outward slightly
rectifying and reversed at 15 mV (n=17, p≤.05, Fig.2.14 B). At a hold-
ing potential of -70 mV, NGF induced a current that reverses at 25
mV (n=17, data not shown). These data reveal that NGF modulates
microglial currents and as such can be considered functionally active
on microglia in an ex vivo setting. Emerging evidence is showing that
stimulation of microglia by activation of glial receptors affects neuro-
transmission [362] [363]. Therefore, we hypothesized that also NGF
may indirectly modulate glutamatergic neurotransmission by acting
on microglial cells. To test this possibility, we first investigated the
action of NGF on miniature excitatory postsynaptic currents (mEP-
SCs) recorded from pyramidal neurons. Bath application of NGF (2
CHAPTER 2. RESULTS 103
1mug/µl) for ten minutes significantly increased both the amplitude
and frequency of mEPSCs (from 20.45±0.97 to 22.90±1.00 pA and
from 5.50±0.71 to 7.43±1.14, n=22; p≤.01 and p≤.05 respectively;
Fig.2.15 A).
These enhancements were, at least partly, due to TrkA receptor
activation, since anti-TrkA mAb MNAC13 counteracted the increase
of both amplitude and frequency by NGF (from 25.85 ± 1.188053 to
26.28981 ± 1.621783) and frequency (from 6.30 ± 1.249805 to 7.10
± 1.535248, n=15; p=.12 and p=.07 respectively; Fig.2.15 B). Then,
we carried out experiments in the presence of minocycline, which pre-
vents microglia activation [364]. Minocycline (100 nM) inhibited the
NGF-induced increase of mEPSC frequency, without affecting the rise
in amplitude (from 2.98 ± 0.58 to 3.43 ± 0.55 Hz and from 18.21
± 1.25 to 20.01 ± 1.23, p=.5 and p≤.05 respectively). Altogether,
these data strongly suggest that NGF acts on microglia to modulate
glutamatergic neurotransmission.
7 NGF and microglia in the pathological
condition: Alzheimer’s Disease
We then decided to assess the effect of NGF on microglia in the context
of pathology, specifically one marked by protein aggregation such as
Alzheimer’s disease. Microglia are important players in the pathogen-
esis of neurodegenerative disorders and they are being studied either
as promoters of disease or physiological tools to be exploited to help
with disease outcome. In vitro, we assessed the inflammatory profile
of cells exposed to the proinflammatory amyloid peptide when NGF
was in the culture medium, and finally we studied Aβ pathology in
neuron-microglia cocultures and the effect of NGF on this in vitro
neuroimmune interface. We tested the phagocytic and degrading ac-
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tivity of microglia towards Aβ after NGF treatment in vivo. The
pro-phagocytic activity was then confirmed an ex vivo assay on acute
slices treated with NGF. Then, we found that the treatment with NGF
protects neuronal spines from Aβ-induced toxicity.
8 NGF counteracts Aβ proinflammatory
effect on microglia.
Aβ provides an inflammatory stimulus to microglial cells [365]. Given
the above-mentioned effects of NGF on microglial cells, it was of in-
terest to ask whether and how NGF can modulate the Aβ-induced
inflammatory profile in microglia. To this aim, we profiled the expres-
sion of inflammatory cytokines and chemokines in primary microglia
in response to NGF, Aβ and Aβ with NGF, with an inflammation an-
tibody array. Looking at the heatmaps (Fig.2.16 B) , we can macro-
scopically see the inflammatory activity of Aβ by the prevailing of
the red bars (increased quantity of cytokines). NGF seems to carry
out the opposite effect: not only it is intrinsically anti-inflammatory
when administered on his own but, when given in concomitance with
Aβ, NGF treatment appears to counteract the inflammatory stimu-
lation by Aβ, returning cytokines to levels of the untreated sample.
This effect by NGF was quantified by the PCA analysis (Fig.2.16 A),
that shows NGF treated cells to be at opposite sides of the PC1/PC2
plane, with untreated cells having an intermediate position - closer
to the NGF groups - and Aβ treated cells clustering elsewhere Thus,
NGF is very effective in reverting the pro-inflammatory state of mi-
croglia induced by Aβ, while it has only a moderate effect on the
inflammatory phenotype of naive microglial cells, consistent with the
transcriptomic study we presented in Fig.2.10 A-B and Fig.2.11 C-D.
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9 NGF promotes the internalization of
soluble toxic Aβ oligomers through TrkA
signaling.
Microglia play an important role in the engulfment of different forms
of the Alzheimer’s hallmark Aβ peptide. While microglial cells en-
docytose fibrillar Aβ by phagocytosis, the soluble forms of the Aβ
peptide are engulfed in microglia by macropinocytosis [257]. Thus,
we asked whether NGF, which supposedly increases macropinocytosis
in our previous experiments, differentially regulates the engulfment of
fibrillar Aβ (fAβ) and soluble Aβ (sAβ). To this aim, we incubated
primary microglia with either fluorescent fAβ or sAβ and we tested
and measured the effect of NGF by FACS, IF and WB. Consistently
with our results with dextran and beads, FACS analysis revealed that
NGF did not increase the engulfment of fAβ (Fig.2.17 A) , but in-
creased significantly the macropinocytosis of sAβ (Fig.2.17 B). The
quantity of sAβ and AbOs - pure oligomers produced in vitro [366] -
inside primary microglial cells after NGF treatment (from both B6129
and Cx3Cr1-GFP) was also measured by immunofluorescence confirm-
ing an increase in the internalization of the soluble peptide (Fig.2.18
A e B) . To quantify the increase of NGF-induced Aβ engulfment, and
to distinguish different Aβ species, we performed western blot analysis
for Aβ on cell extracts. We found that NGF determines a two-fold
increase of the internalized Aβ dimers and trimers (Fig.2.19 A) .
To discern the involvement of the different NGF receptors in the
internalization of Aβ, we interfered with TrkA and p75NTR signalling
through specific inhibitors: K252a, which blocks TrkA phosphoryla-
tion and signaling, and TAT-pep5, a p75NTR signalling inhibitor.
K252a, and not TAT-pep5, was able to block the increase in the up-
take of AbOs in response to NGF (Fig.2.19 B). On the other hand,
TAT-pep5 does not interfere with NGF-dependent increase in AbOs
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internalization (Fig.2.19 B). Thus, we conclude that NGF is able to
increase selectively macropinocytosis of soluble Aβ oligomers in mi-
croglia by a TrkA-dependent mechanism.
10 The fate of internalized sAβ following
NGF treatment
What are the consequences of the increased macropinocytosis of Aβ
oligomers induced by NGF? The Aβ engulfed by microglia could be ei-
ther accumulated inside the cells, expelled through exocytosis/released
in exosomes, or digested. Transcriptome analysis revealed a strong
modulation by NGF of genes involved in protein digestion, giving us
cause to test the hypothesis that the degradation of internalized sAβ
might be modulated in response to NGF. We followed the fate of sAβ
using lysotracker, a dye that marks lysosomes (Fig.2.20 A) . The sAβ
peptides (green) is internalized by BV2 microglial cells following NGF
incubation and colocalize with lysotracker (red), suggesting that the
engulfed material might go through lysosomal degradation. In order to
quantify such degradation and the hypothetical release of Aβ - such
as suggested by (Joshi et al., 2014) [367] - we proceeded as follows
(Fig.2.20 B): BV2 microglial cells were treated with soluble Aβ for
3hrs, then supernatant was collected and cells were washed to remove
the Aβ excess. We then monitored Aβ intracellular and extracellular
levels in parallel experiments at 5, 9 and 21 hrs, by WB of cell extracts
- reflective of degradation - and ELISA of supernatants - to detect ma-
terial that was expelled. This experiment reveals that not only NGF-
treated cells ingest more Aβ than non-treated cells (Fig.2.20 C-D) -
in accordance to our previous results - but also that NGF-treated mi-
croglial cells digest a greater amount of Aβ (Fig.2.20 D) and release
a smaller fraction of the ingested Aβ peptide into the extracellular
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compartment, compared to untreated control cells (Fig.2.20 E).
11 Phagocytosis of Aβ ex vivo
To assess the translatability to a physiologic environment, we also
tested phagocytosis ex vivo in acute brain slice preparations from
CX3CR1-GFP mice. The acute slice was incubated for 3 hrs with
NGF and s555-Aβ, the slice was then fixed, cut to 45 µm thick slices
and mounted on glass slides to quantify internalization of fluorescent
Aβ by GFP+ cells. We found a significant increase of internalized
Aβ in microglial cells from brain slices that were incubated with NGF
(Fig.2.21), suggesting indeed that the effect can translate to microglia
in vivo.
12 NGF protects against Aβ induced spine
toxicity, rescuing spine density and LTP
In the previous sections, we demonstrated the ability of NGF-stimulated
microglia to effectively internalize and process Aβ, thus removing toxic
soluble oligomers from the medium. It is known that Aβ oligomers
decrease spine density both in vitro and in vivo, and impair synaptic
long-term potentiation (LTP) [368] [369] [370] [371]. In the healthy
brain, an established physiological function of microglia is the regu-
lation of synapse number by a phagocytic process known as synaptic
pruning [3] [1] [2] [372]. Therefore, we asked whether NGF might regu-
late the dendritic spine phagocytosis activity of microglia. To this aim,
we performed co-cultures of primary microglia with mature neurons
and we quantified spine density following NGF treatment (Fig.2.22 A)
. The number of PSD95 positive puncta was lower on neurons cultured
with microglia than in control neuronal cultures; this reflects the nor-
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mal phagocytic activity of microglia on synapses [373]. On the other
hand, NGF treatment of microglia does not determine any further
reduction of spine number compared to untreated microglia-neuron
co-cultures (Fig.2.22 B): thus, NGF does not modulate the phagocy-
tosis of synapses by microglia. We next asked if NGF-treated microglia
could rescue spine loss mediated by sAβ exposure. Surely, in our con-
trol experiment, sAβ addition to pure neuronal cultures significantly
decreases spine density by 50%, a decrease that could not be rescued
by NGF treatment alone; however, in neuron-microglia co-cultures,
while Aβ-induced spine loss could still be detected in the untreated
samples, concomitant activation of microglia with NGF completely
prevented the decrease in spine density, pointing towards microglia as
the mediators of NGF neuroprotective action (Fig.2.22 B). We con-
clude that NGF can prevent Aβ-mediated spine loss in a microglia-
dependent manner. The effects of Aβ on spine number is paralleled
by its negative effects on synaptic potentiation in plasticity paradigms
[374] [375]. We therefore sought to investigate the interplay between
NGF, microglia and spines in a plasticity protocol. We quantified
spine potentiation measuring the total amount of GluA1 AMPA re-
ceptors in neurons under resting conditions or after glycine-induced
chemical LTP (GI-LTP) (as in Fortin et al., 2010 and Ahmad et al.,
2012) [376] [377]. As previously reported, the staining intensity of
synaptic GluA1 AMPA receptors increased in pure neuronal cultures
1 hr after GI-LTP induction (Fig.2.23).
Under our conditions, in microglia-containing cultures, neurons
were found to be more sensitive to GI-LTP induction: GI-LTP in-
duced a greater increase of GluA1 synaptic staining (36 % increase
with respect non-LTP cultures), when microglia was present, com-
pared to control cultures without microglia (15,76 % with respect
to non-LTP cultures) (Fig.2.23). This suggests an enhancement of
synaptic potentiation by microglia, an i vitro correlate of the evidence
suggesting a role for microglia in spine formation and potentiation in
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vivo [141] [1]. SAβ exposure prevented the spine potentiation by GI-
LTP, since the levels of synaptic GluA1 were not significantly different
between glycine-stimulated and control cultures. The presence of mi-
croglia alone was not sufficient to rescue the synaptic GluA1 levels
after sAβ incubation in sister cultures containing microglia (Fig.2.23).
Instead, NGF-stimulated microglia cells were able to rescue the im-
pairment of synaptic potentiation caused by sAβ. In fact, in NGF-
treated microglia-neurons co-cultures, synaptic GluA1 levels were sig-
nificantly higher after GI-LTP, even in the presence of sAβ (Fig.2.23).
This was not due to a direct action of NGF alone on neurons, since
in pure neuronal cultures NGF exposure was not sufficient, per se, to
drive a significant change of synaptic GluA1 levels after GI-LTP in the
presence of sAβ (Fig.2.23). From these data we conclude that not only
NGF-stimulated microglial cells are able to block spine loss induced
by sAβ (Fig.2.22 A-B), but they can also attenuate sAβ impairment
of spine potentiation (Fig.2.23).
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Figure 2.15: NGF affects microglial currents thereby enhancing exci-
tatory neurotransmission. (A) Left, example traces of AMPAR mEP-
SCs recorded from a pyramidal neuron at 270 mV, in control (ctrl)
and after NGF (20 γ), in the presence of picrotoxin (100 mM) and
TTX (1µM). Right, bar histograms of group data showing the NGF-
mediated increase of mEPSCs amplitude and frequency. (n=22, ∗
p≤0.05, ∗∗ p≤0.01, paired sample t test. (B) Same as in c but in the
presence of the anti-TrkA, MNAC13. Note that 20 γ NGF did not
enhance mEPSC amplitude and frequency when TrkA receptors are
blocked (n515, p=.012 and p=.7 for amplitude and frequency, respec-
tively; paired sample t test). (C) Left, example recordings of mEP-
SCs before and during NGF in the presence of 100 nM minocycline
(mino). Right, population plots of mEPSC amplitude and frequency
in minocycline, before (black bar) and during NGF (red bar), show-
ing that NGF increased selectively the mEPSC frequency but not the
amplitude when microglia activation was blocked (n=13, p≤.05 and
p=.5, paired sample t test. Data are values from single cells (gray
filled circle) and mean±SEM (bars).
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Figure 2.16: Anti-inflammatory effect of NGF on microglia primed
with Aβ. (A) PCA analysis of the inflammatory array. In the graph,
two biological replicates of four different treatments were plotted. PC1
and PC2 represent the first two principal components, the proportion
of variance (POV) held by these components is reported in brackets
as percentages. (B) Inflammation array of primary microglia treated
with NGF, Aβ, or Aβ and NGF reported as heatmaps, the scale bar
represents the minimum and maximum levels of protein mean. Anal-
ysis was performed on RStudio (Boston, MA).
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Figure 2.17: NGF increases the macropinocytosis of soluble Aβ but
not the phagocytosis of fibrillar Aβ. Flow cytometry (580-650nm ab-
sorption) to count the number of cells that phagocyte the differents
peptides. Primary microglia from wild type mice were incubated with
1µM of fAβ or sAβ and 100 ng/ml NGF. Uptake was quantified us-
ing flow cytometry and compared with control non treated cells (A)
Internalization of fAβ is not affected by NGF treatment. (B) Internal-
ization of the soluble peptide is increased after NGF treatment. Con-
trols: NGF has a similar effect to PMA (an activator of macropinocy-
tosis), CytochalasinD: inhibitor of endocytic processes (mean ± SD,
∗ p≤0.05, Student’s T-test).
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Figure 2.18: NGF increases the engulfment of sAβ peptide and ABOs:
Immunofluorescence. Primary microglia from CX3CR1-GFP (A) and
wild type mice (B) were incubated respectively with 1 µM of fluo-
555 sAβ peptide and ABOs, from 7pA2 supernatant, in presence or
absence of 100 ng/ml NGF (10 µm scale bar, 20¡n¡30, ∗ p≤0.05 ∗ ∗
p≤0.001, Kolmogorov-Smirnov test).
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Figure 2.19: The modulation of microglial phagocytic activity is TrkA
dependent. (A) Western Blot of primary microglia treated with 1µM
of sAβ with or without NGF. Values are expressed as relative levels
to controls (mean ± SD, ∗ p≤0.05, Student’s T-test). (B) Primary
microglia treated with 200 nM K252a, intracellular TrkA inhibitor
and with 1µM TAT-pep5 p75NTR, inhibitor of p75NTR intracellular
signaling. Values are normalized to the signal of samples treated with
only sAβ (mean ± SD, ∗ p≤0.05, Student’s T-test).
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Figure 2.20: sAβ is digested and not released in the extracellular
environment in cells treated with NGF in BV2 microglial cells. (A)
Soluble Aβ is rapidly trafficked to lysosomes for degradation. Confocal
imaging of live BV-2 microglia 45 min of 1 µM soluble Aβ1-42-488
demonstrated localization of Aβ (green) within lysosomes. Lysosomes
were stained using LysoTracker (red). (B) Experimental design for
the degradation experiment (C) Western blot of cells lysate. (D) The
histogram shows the degradation measure as the delta between the
protein levels at the n time point and (n+1) time point and thus
represents the amount of protein that has been digested from one time
point to the other. (E) Extracellular Aβ levels measured by ELISA.
The data represent the outcome of three independent experiments
(mean ± SD, ∗ p≤0.05, Student’s T-test).
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Figure 2.21: NGF increases the engulfment of sAβ ex vivo. Represen-
tative images of confocal stack acquisitions from 45 µm Cx3Cr1-GFP
slices. Ex vivo 200 µm slices were first treated with 0,1 µM sAβ and
with/without of 100 µg/ml NGF then analyzed by IF for Aβ content
(mean ± SD, ∗ p≤0.05, Student’s T-test.
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Figure 2.22: NGF protects against Aβ-induced spines toxicity in a
microglial dependent fashion. (A) Representative images from con-
focal acquisition show PSD95 (white) puncta in neurons and in co-
cultures +/- NGF. (B) Representative images of confocal acquisition
of neuronal spines labeled with actin (white) and the dendrites mag-
nification +/- sAβ (violet) in microglia (green)-neuronal co-cultures;
(200¡n spines¡500 for two independent experiments, mean ± S.E.D ∗
p≤0.05 ∗ ∗ ∗ p≤0.001, one-way ANOVA test, followed by a post-hoc
Bonferroni test).
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Figure 2.23: NGF protects against Aβ-induced loss of potentiation
in neuron-microglia cocultures. (A) Effect of GI- LTP induction on
GluA1 receptors (white) in different conditions, +/- microglia (green),
+/- NGF, +/- sAβ. Histograms show the values of each experimental
condition. (200<n spines<500 for two independent experiments, mean
± S.E.D ∗ p≤0.05 ∗ ∗ ∗ p≤0.001, one-way ANOVA test, followed by
a post-hoc Bonferroni test).
Results highlights
• Microglia are NGF target cells.
• NGF modulates microglial motility and affects neuronal activity
and physiology via microglia.
• In the context of Aβ pathology, NGF induces a neuroprotective




So far in the literature, despite some scattered evidence [345] [328]
[147] [347] [348] [12] no clear systematic evidences about microglia
relationship with NGF are reported and nothing is known about a
potential neuroprotective role of NGF mediated by microglia.
Indeed, the main cellular targets of the neurotrophin Nerve Growth
Factor (NGF) [14] in the central nervous system are considered to be
the cholinergic neurons of the basal forebrain (BFCNs) [15], while its
sources are mainly cortical and hippocampal neurons [16]. Interfer-
ing with trkA-NGF signalling has been related before to mechanisms
driving neurodegeneration: in the AD11 transgenic mouse model [17]
[18] the expression of anti NGF antibodies selectively neutralizing ma-
ture NGF in the adult brain determines a progressive comprehensive
neurodegeneration, with neuroinflammation as the earliest observed
change, at a presymptomatic phase [19] [20]. A similar progressive
neurodegeneration is observed in transgenic mice expressing a neu-
tralizing anti-TrkA antibody in the adult brain [18] Changes in NGF
homeostasis in the brain have also been linked to Alzheimer’s disease
[22] [378]. On the other hand, the loss of NGF-TrkA signaling in the
CNS, obtained by conditionally deleting NGF or TrkA genes in CNS
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cells derived from nestin-positive cells, has proven not to be sufficient
in inducing cognitive impairments in mice [23], suggesting to us that
another non neuronal target cell of NGF might be involved in the
occurrence of the neurodegeneration phenotype in the AD11 mouse
model.
In this thesis I have provided stringent evidence that microglia are
target cells for NGF in vitro and ex vivo. My analysis on the mouse
cortex and primary microglia demonstrates that microglia express the
NGF receptor TrkA. In these cells, NGF is able to elicit the appro-
priate intracellular signaling, resulting in a modulation of a variety of
physiological activities of microglial cells. The activity of microglia is
intimately associated with their morphology. Most of the functions of
these cells are accomplished through structural changes [5] [40]: from
the extension and retraction of their branches in response to physiolog-
ical stimuli to the migration of the entire cell body to the site of injury.
Microglia motility has also been recently correlated with the ability
of pruning synapses [2], and therefore represents an important feature
when trying to estimate microglial activity in physiological and patho-
logical situations. My gene expression profiling data and time-lapse
recordings respectively suggest a modulation of genes involved in cy-
toskeletal reorganization and variations in membrane dynamics after
incubation with NGF. Then I focused on the possible consequences of
NGF activity on microglial cells in pathological conditions by using Aβ
as a gold standard. Consistently with the hypothesis of neuroinflam-
mation induced by anti-NGF deprivation [20], I found that microglial
cells treated with NGF not only respond in a non-inflammatory fash-
ion, but also they seem to be refractory to the inflammatory stimulus
of Aβ. Hence, we conclude that NGF is capable of reversing the in-
flammatory effect brought on by Aβ, while resulting only slightly anti-
inflammatory. These protective effect was suggested also by Alexaki
et al in their recent research where they demonstrated how the de-
hydroepiandrosterone (DHEA), the most abundant circulating steroid
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hormone in humans, binding to TrkA, exerts its neuroprotective effect
reducing the microglia mediated inflammation response through TrkA
phosphorilation. In this way they demonstrated how TrkA signaling
is a potent regulator of microglia mediated inflammation [379], con-
firming our results of protective effect of NGF on microglia activity.
In my analysis it was also shown that NGF is capable of en-
hancing specifically one type of endocytic process in microglial cells,
macropinocytosis, which is the mechanism of choice through which
microglial cells clear sAβ [257]. Thus, as a further step in demon-
strating that NGF neuroprotective activity is mediated by microglia,
I demonstrated that, by enhancing macropinocytosis, NGF promotes
sAβ clearance in vitro and ex vivo.
Actually increasing the uptake of sAβ is not enough to provide a
long term protection over the toxicity of the peptide, since internalized
sAβ might be shed again into the medium prior to its degradation. In
fact, microglia can release internalized fibrillar Aβ and convert it in
neurotoxic forms through the shedding of microvesicles [367]. More-
over, it is still not clear if microglial cells are actually able to digest
sAβ efficiently [114] [380][381], due to the evidence suggesting that
microglia near plaques is functionally impaired [382]. Here, I showed
that NGF not only increases Aβ uptake by microglia but enhances its
degradation, consistent with the transcriptome modulation involving
lysosome and degradation pathways. Alzheimer’s Disease has been
described as a synaptopathy, entailing a dysfunction of synaptic func-
tion [383] [384] [385]. Synapse loss is indeed an early sign of AD and
the process has been directly correlated with Aβ as the most likely
culprit. High concentrations of Aβ or Aβ oligomers inhibit the synap-
tic plasticity responses [386] [387] [375]. Aβ has been proven to be a
key player in synaptic plasticity also at physiological concentrations:
while short exposures with low concentrations of the peptide actually
enhance synaptic plasticity, longer exposures lasting several hours re-
duce it [388]. This underlines the importance of the homeostasis of
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Aβ peptide levels and thus of microglia as an important factor in its
clearance and in this homeostatic process. Under physiological con-
ditions microglial cells regulate dendritic spines, either pruning away
superfluous spines during development [154] or increasing spine density
as observed in the developing somatosensory cortex [140] [141]. We
therefore assessed whether NGF is capable of modulating Aβ effect on
spine number reduction, in relation to this microglia-neuron commu-
nication. In microglia-neuron co-cultures, NGF proves to rescue the
spine loss mediated by Aβ, an effect that is specifically dependent on
microglia. Plasticity was also studied in vitro by evaluating the effi-
cacy of chemical LTP in the presence of microglia. Interestingly, spine
potentiation, measured as AMPAR intensity increase, is stronger on
neurons when cultured with microglia. While Aβ causes a dramatic
loss of efficacy of chemical LTP in neuron-microglia co-cultures, NGF
is able to fully rescue spine potentiation in these conditions. The effect
is completely dependent on the presence of microglia in the cultures,
since neurons alone do not show the rescue in response to NGF. In-
tranasal administration of an NGF variant was recently proven to be
highly neuroprotective in an AD mouse model. 5xFAD mice chron-
ically treated with the neurotrophin showed a dramatic reduction of
the plaque load, with a clear evidence of the involvement of microglial
cells in the clearing of Aβ [389]. In that study, the neurotrophin,
added to 5xFAD slices (which present LTP deficits), determined a
rescue of plasticity, which was dependent on TrkA activity. Our re-
sults go into the direction of attributing these events to the action of
NGF on microglial cells. Indeed, our electrophysiological recordings
on neurons suggest that by affecting microglial physiological activ-
ity, NGF is capable of influencing glutamatergic transmission. In-
deed, we demonstrate that tampering with NGF-TrkA signaling in
microglia affects negatively glutamatergic neurotransmission. Thus,
NGF-activated microglia might result neuroprotective in Aβ pathol-
ogy not only by lowering the amount of circulating Aβ - per se toxic
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to neurons - but also by aiding neurons in plasticity tasks. As a mes-
sage from neurons to immune cells, NGF can serve as a regulator of
the activity of the immune system on the nervous system: a mediator
of neuroimmune communication. To sum up, these data are pointing
towards the myeloid cells of the brain as the culprit for the severe
neurodegeneration observed in anti NGF or anti TrkA mice. Indeed,
NGF is capable of steering microglia toward a neuroprotective pheno-
type against Aβ, adding an important element to the rationale for the
therapeutic use of NGF in AD.
As a consequence of our results showing the crucial role of NGF in
regulating microglia activities and physiological functions, I postulate
that the reduced NGF activity might play an early causal role in the
onset of the progressive AD11 neurodegeneration phenotype, modify-
ing the morphology of microglia in vivo, and above all modifying the
ability of these cells to conduct their physiological protective function
in the brain. In order to be able to charge the lack of NGF signal-
ing on microglia as being responsible for the AD phenotype, in future
studies it would be interesting to verify directly the role of NGF sig-
naling loss on microglia cells. To identify the specific and direct role of
NGF signalling on microglia to the onset of neurodegeneration in the
mouse brain, and, more generally, to the onset of AD eziopathology
in humans, it would be useful to design a transgenic animal model
with a conditional TrkA gene deletion in microglia, and investigate
whether this is sufficient to trigger a progressive neurodegeneration as
that observed in the AD11 model.
Thus, if the lack of NGF is responsible for the AD phenotype, due
to the loss of NGF-TrkA activity in microglia cells, this mouse model
should present a progressive AD like phenotype, as in AD11 mice, with
changes in microglia morphology and inflammatory activation at the
early stages. We cannot exclude that the selective deletion of TrkA
gene in microglia cells might on its own not be sufficient to trigger
neurodegeneration, whose onset might require a second independent
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signal. In any case, these future ongoing experiments would provide a
definitive clarification of the early causes and of the effector cells in-
volved in the progressive neurodegeneration observed in the anti NGF
AD11 mice and, by extension, in the human pathology. More impor-
tant, in a therapeutic perspective the results I have obtained in the
thesis provide a strong rationale for the use of NGF as a therapeutic
neuroprotective agent in the brain for a large class of neurodegenera-




Adult C57BL/6 (Charles River Laboratories, Como, Italy) mice ex-
pressing green fluorescent protein under the fractalkine receptor pro-
moter CX3CR1 (Cx3cr1/GFP+/+ mice) and B6129 mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME). Genotyping
of CX3CR1-GFP mice was performed by PCR analysis of tail DNA
(IDT 14276: 5’-GTC TTC ACG TTC GGT CTG GT-3’, IDT 14277
5’-CCC AGA CAC TCG TTG TCC TT-3’, IDT 14278 5’-CTC CCC
CTG AAC CTG AAA C-3’). AD11 mice and VH mice control (Ru-
berti, Capsoni et al. 2000), 1 and 6 months old, were used. Littermates
were used as controls for the IHC, since AD11 has a C57BL/6 x SJL
background. Genotyping was performed by PCR analysis of tail DNA.
All experiments with mice were performed according to the national
and international laws for laboratory animal welfare and experimenta-
tion (EU directive n. 2010/63/EU and Italian DL n. 26 04/03/2014).
Mice were kept under a 12-h dark to light cycle, with food and water
ad libitum.
Cell cultures
The immortalized BV-2 murine microglial cell line (Blasi, Barluzzi,
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Bocchini, Mazzolla, Bistoni, 1990) was grown and maintained in RPMI
(Thermo Fisher Scientific, MA, USA #11835-063) medium contain-
ing 1% penicillin/streptomycin (Euroclone, MI, Italy #ECB3001D),
1% Glutamax (Thermo Fisher Scientific, MA, USA; #35050-038) and
10% fetal bovine serum (FBS) (Euroclone, MI, Italy #ECS0180l) in
5% CO2 at 37◦C. Primary microglial cells were derived from the brains
of B6129 or Cx3cr1/GFP+/+ mice at postnatal day 3-4 as previously
described (Butovsky et al., 2014). Cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM/F12) (Thermo Fisher Scientific,
MA, USA #21331-020) containing 1% penicillin/streptomycin, 1%
Glutamax and 10% FBS in 5% CO2 pH 7.4 at 37 ◦C. Microglia were
separated from the mixed primary glial cultures by mild shaking, they
were re-suspended in DMEM/F12 with 1% penicillin/streptomycin,
1% Glutamax and 10% FBS - this is the standard culture medium
unless otherwise stated - and plated on the appropriate support 18hrs
before the experiments to allow cells to attach to the substrate. Pri-
mary cortical and hippocampal neurons were prepared at postnatal
day 0 as described (Beaudoin et al., 2012). Briefly, animals were de-
capitated, the brain was rapidly excised and placed into ice-cold Hanks
Buffered Saline Solution (HBSS) (Thermo Fisher Scientific, MA, USA;
#14180046). Hippocampi and cortex were removed and digested for
15 min at 37◦C in DMEM-F12 containing 0.1% of trypsin (Thermo
Fisher Scientific, MA, USA). Thereafter, tissue was transferred in cul-
ture medium containing 10% FBS and gently disrupted using a flame-
polished Pasteur pipette. Following centrifugation at 4◦C for 8 min
at 800 r.p.m. cells were resuspended in fresh DMEM containing 1%
Glutamax, 10% FBS, 2% B27 supplement (Gibco, MA, USA, #17504-
044), 6 mg/ml Glucose, 12,5 µM Glutamate, 10µg/ml Gentamicin
(Gibco, MA, USA, #15710-049) and plated at a density of approx.
150,000 cells per coverslip after proper poly-D-lysine coating (Sigma
Aldrich, MO, USA, #P1024). Cells were kept at 37◦C in 5% CO2. Af-
ter 12-24 hours, medium was replaced with pre-warmed Neurobasal A
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medium (Thermo Fisher Scientific, MA, USA #10888-022) containing
2% of B27 supplement, 2.5 µM Glutamax, and 10 µg/ml Gentamicin.
The second day 2.5 µM AraC (Sigma, Aldrich, MO, USA; #C1768)
was added at the medium. The experiments were performed at DIV
17-19.
Immunoblot analysis
NGF signaling: Primary B6129 microglia were plated in 6 well plates
at a density of 5X105/well in culture medium. After 18 hrs, cells were
serum-starved for 16 hrs before the start of the treatments. Cells were
treated for 0, 5, 15, 30 min with NGF 100 ng/ml and sequentially
collected and lysed in ice-cold RIPA buffer (50 mm Tris-HCl, pH 7.6,
150 mm NaCl, 1% Igepal, 1 mm EDTA, 1% SDS, 0,5% sodium deoxy-
cholate, 1x protease and phosphatase inhibitor cocktails (Roche, Basel;
CH)). After sonication, cells were collected by centrifugation for 15
min at 4 ◦C (13,000 r.p.m.). Protein concentrations of the cell lysates
were measured using the Bradford method. Lysates (20 microng) were
then separated on a 10% SDS-PAGE, transferred to a nitrocellulose
membrane, and analyzed by Western blotting. Phagocytosis of Aβ:
Primary B6129 microglia were first plated in 6 well plates at a density
of 5X105/well in culture medium. After 18 hrs, they were treated with
1 µM soluble Aβ for 3 hrs with or without 100 ng/ml NGF. After col-
lection, they were lysed in ice-cold RIPA buffer and electrophoresed on
a 4-12% NuPAGE Bis-Tris precast gel (Thermo Fisher Scientific, MA,
USA; #WG1401BX10). After transfer in nitrocellulose, the mem-
brane was boiled in PBS for 10 min, blocked for 1h and incubated
with the appropriate primary antibodies. Inhibitors of NGF-receptors
used: 200 nM K252a (Abcam, Cambridge, UK; #ab120419), TAT-
pep5 p75NTR (Millipore, CA, USA; #506181) (Yamashita Tohyama,
2003), were added 30 min before Aβ and NGF. The following primary
antibodies were used: anti-Aβ 1-16 1:1000 (clone 6E10 #SIG-39320);
anti-TrkA 1:1000 (Millipore, CA, USA; #06-574), anti-pTrkA 1:1000
(Y794) (Rajagopal, Chen, Lee, Chao, 2004) kindly provided by M. V.
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Chao (New York University School of Medicine, New York, USA) anti
Akt 1:1000 (Cell Signaling Technology, MA, USA; #C67E7) , anti
p-Akt 1:1000 (Cell Signaling Technology #130386), ant-Erk 1:1000
(Promega, WI, USA; #V114A), anti-pErk 1:1000 (Cell Signaling Tech-
nology, MA, USA; #4370S), anti-c-Jun 1:1000 (Cell Signaling Tech-
nology, MA, USA; #60A8) , anti-phospho-c-Jun 1:1000 (Cell Signaling
Technology, MA, USA; #9261), anti-p75 1:1000 (Millipore, CA, USA;
AB1554), anti-GAPDH 1:20000 (Fitzgerald, MA, USA; #10R-G109a),
anti-tubulin 1:20000 (Sigma Aldrich, MO, USA; #T5168). After in-
cubation with the appropriate HRP-conjugated secondary antibody
(Santa Cruz, TX, USA; anti-mouse #sc-2005, anti-rabbit #sc-2004),
membranes were developed using ECL-enhanced chemiluminescence
kit (Bio-Rad, CA, USA). Densitometric analyses were performed us-
ing the NIH ImageJ 1.44p software.
Immunocytochemistry
Immunofluorescence for NGF receptors: Primary microglia were plated
on coverslips in 24-well plates coated with poly-D-lysine (1x105 cells/well)
in culture medium. After 18 hrs, cells were fixed with 2% PFA, and
blocked for 1 hr at room temperature. Coverslips were incubated
overnight at 4◦C in primary antibody: anti-Iba1 1:500 (WAKO, Os-
aka, Japan; #019-19741) or anti-Iba1 1:500 (Abcam, Cambridge, UK;
#Ab107159), anti-TrkA 1:100 (MNAC13 (Covaceuszach, Cattaneo,
Lamba, 2005)), anti-P75 1:500 (Millipore, CA, USA; AB1554). Im-
munofluorescence for Aβ uptake: Primary microglia were plated on
coverslips in 24-well plates at a density of 1x105 cells/well in culture
medium. Then they were treated with 1 µM soluble 555-labeled Aβ
(s555-Aβ) (Anaspec, Fremont, CA, USA; #As-60480) or AβOs (Meli
et al., 2014) for 3 hrs in either presence or absence of 100 ng/ml NGF.
Cells were washed three times with cold PBS, fixed in 2% PFA and
permeabilized with 0.1% Triton X-100. Cells were blocked for 1 hr
and stained with primary antibodies anti-Iba1 1:500 (WAKO, Osaka,
Japan; #019-19741;) and with anti Aβ antibody A13 1:1000 (Meli,
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Visintin, Cannistraci, Cattaneo, 2009), then they were washed three
times with PBS and incubated with mouse antibody anti-epitope V5
(Sigma Aldrich, MO, USA #V8137;1:5000). After three washings,
cells were incubated for 1 hr with appropriate secondary antibod-
ies (1:500) (anti-rabbit Alexa-Fluor 555, anti-mouse Alexa-Fluor 488,
Thermo Fisher Scientific, MA, USA; A-21428;A-21201). Coverslips
were mounted on glass slides in Fluoromount (Sigma Aldrich, MO,
USA #F6057) and confocal images were acquired using a Leica SP2
confocal microscope (Leica Microsystems, Wetzlar, Germany).
Immunofluorescence (IF) on slice
IF for NGF receptors/microglia/astrocytes detection: Adult (P80-
90) C57BL6J mice were sacrificed with a lethal dose of carbon diox-
ide and immediately underwent a perfusion procedure. Blood was
firstly transcardially washed out with cold phosphate buffer saline so-
lution (PBS), then tissues were fixed with cold 4% paraformaldehyde
in 0.1 M pH 7.4 phosphate buffer (PBS) with a peristaltic pump.
Brains were dissected, postfixed for 18-22 hrs at 4◦C, washed from
paraformaldehyde with PBS and cryoprotected in 30% sucrose/PBS
at 4◦C overnight. Dry ice frozen brains were cut into 40 µm coro-
nal sections with a cryostat microtome (Leica Microsystems, Wetzlar,
Germany) at -20◦C, including neocortex. Sections were rinsed for
three times in PBS and incubated with a mix of primary antibodies
in PBS 0.3% Triton X-100 (Applichem, BioChemica, Darmstadt, Ger-
many) overnight at room temperature. Microglia was stained with
rabbit anti-Iba1 (Wako, Osaka, Japan, 019-19741, 1:800) or rat anti-
CD11b (Serotec; Kidlington, UK, MCA711, 1:300) depending on the
second primary antibody used. Astrocytes were stained with rab-
bit Anti-Glial Fibrillary Acidic Protein (Dako, Cytomation, Glostrup,
Denmark, Z0334, 1: 500) or goat Anti-Glial Fibrillary Acidic Protein
(Santa Cruz Biotechnology, California, USA, sc-6170, 1:300). NGF re-
ceptors were identified by anti-TrkA (clone MNAC13, 1:300, (Cattaneo
et al., 1999)) and anti-P75 (Promega Corporation, Madison, WI, USA,
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G3231, 1:300). After three 10 min rinses in PBS at RT, sections were
incubated for 2 hrs at RT in a mix of the appropriate secondary an-
tibodies - anti-mouse/rabbit/goat/rat Alexa-Fluor 488/555/649 con-
jugated (Thermo Fisher Scientific, MA, USA; A-21428 diluted 1:500)
- followed by three 10 min rinses in PBS. DAPI was applied for 5
min in the second rinse, dissolved in the PBS solution. To exclude
non-specific signals of secondary antibodies, sections from each group
of animals have also been stained with secondary antibody alone, fol-
lowing the same experimental procedure but omitting the primary
antibodies.
Flow cytometry for phagocytosis analysis of beads, dex-
tran or Aβ
Sample preparation: Primary microglia were plated in 6 well plates at
a density of 5x102 cells/well. The fluorescent material to be phagocy-
tosed - was placed in the culture medium 3 hrs after treatment with
NGF 100 ng/ml. Beads were first opsonized in 50% FBS and PBS for 1
hr RT (Polybead DyedRed 6 µm, Polyscience; PA, USA; Cat#15714),
counted with the Burker chamber and given to cells at a concentra-
tion of roughly 3 beads/cell. Dextran was used at 2.5 mg/ml (Thermo
Fisher Scientific, MA; USA, #D1841 RhodamineB 70,000 MW) while
HiLyte Fluor 555 Aβ42 (Anaspec, Fremont, CA, USA; #As-60480)
was used 1 µM. Cells were exposed to the material for 1 hr, then they
were washed extensively with PBS, and fixed with 2% paraformalde-
hyde for 7 min. Cells were washed again with PBS and collected for
analysis. Data acquisition: A Sorter S3 (BioRad, CA, USA) with a
single 488 nm (100 mW) excitation laser was used. The gating strategy
was decided on the FSC and SCC scatter plots, in order to gate out
debris. Filters are based on the emission spectra of the fluorochromes:
RhodamineB for dextran, DyeRed for beads, HiLyte Fluor 555 for
Aβ42 - 580-650nm (red channel). The total amount of beads, dextran
or Aβ internalized by cells was determined by analyzing the popula-
tion positive for the fluorescent marker conjugated with the material.
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The analysis was performed using the FlowJo software (FlowJo, LLC,
Ashland, Ore., USA). List of concentrations and time of treatment for
inhibitors and activators of macropinocytosis and phagocytosis used to
determine the specific process of internalization activated by NGF ad-
ministration: IFNγ 10 ng/ml (RD, Minneapolis MN, USA Cat. Num-
ber 485-MI), Amiloride 50 µM (Sigma Aldrich, MO, USA; #A3085),
CytochalasinD 10 µg/ml (Sigma Aldrich, MO, USA; #C827). These
were added 20h before phagocytosis assay. Rho/Rac/cdc42 Activator
I (Cytoskeleton, CO, USA; cat. #CN04) was added after a 2 hrs FBS
starvation period and 1 hr and 30min before the beginning of the ex-
periment with beads and dextran. Phorbol 12-myristate 13-acetate
(PMA) 100 nM (Sigma Aldrich, MO, USA #P8139) was added 3 hrs
before the assay.
Microarray transcriptome analysis
Primary microglia were treated with 100 ng/ml NGF for 2 hrs, 8 hrs
or 24 hrs. RNA isolation, amplification, and labeling was performed
using an RNeasy mini kit according to manufacturer’s protocol (Qia-
gen). Total RNA was isolated from these cells using Trizol (Invitrogen)
and DNAse treated by Qiagen columns. Quality and integrity of each
sample was checked using the Agilent BioAnalyzer 2100 (Agilent RNA
6000 nano kit): samples with a RNA Integrity Number (RIN) index
lower than 8.0 were discarded. All the experimental steps involving the
labeling, hybridization, and washing of the samples were done follow-
ing the standard one-color microAgilent protocol. The gene expression
profiling was performed using the Microarray Agilent Platform. 200
ng of RNA was labeled with Low Input Quick Amp Labeling Kit One-
Color (Agilent Technologies), purified and hybridized overnight onto
the Agilent 8X60K whole mouse genome oligonucleotide microarrays
(Grid ID 028005) according to the manufacturer’s instructions for one-
color protocol. The Agilent DNA microarray scanner (model G2505C)
was used for slide acquisition and spot analysis was performed with
Feature Extraction software ver 10.7 (Agilent Technologies). Data
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filtering and analysis were performed using R-Bioconductor and Mi-
crosoft Excel. All the features with the flag gIsWellAboveBG=0 (too
close to background) were filtered out and excluded from the follow-
ing analysis. Filtered data were normalized by aligning samples to the
75th percentile. Differentially expressed genes were selected by a com-
bination of fold change and moderated T-test thresholds (R Limma
test p≤0.05; —Log2 fold-change—¿1.0). Principal Component Analy-
sis, Multi-Dimensional Scaling, Hierarchical Clustering of samples and
volcano plots were computed using the open source R Studio (Boston,
MA,USA).
Live cell imaging
To study microglial motility, primary microglia were plated (3x104
cells) on Glass Bottom Microwell Dishes (35mm), coated with poly-
D-lysine, and left overnight to rest. Then cells were treated with 100
ng/ml NGF for 24 hrs. Cells were imaged for 1 hr through a 40X
objective with a Leica SP2 confocal microscope. Cell dynamics was
analyzed using a homemade Python script (number of cells per experi-
ment = 29). The parameters taken into consideration were: Morphing
speed measures how many times, during the acquisition, cells change
their morphology. Two extremes were fixed as opposite morphologi-
cal endpoints: roundish and polarized (with at least two ramification).
We measured how many times cells shift between these two cell config-
urations. The parameter was used to classify the speed of changes in
morphology. Cell membrane changes describes how cells change their
Area (A) normalized on cell perimeter (p), in particular we measured
∆A/p between two consecutive frames (1 frame/min), giving us an in-
termediary to monitor membrane motility. For the experiment of Aβ
lysosome colocalization, microglial BV-2 cells were plated overnight in
RPMI containing 2µ FBS on precoated culture plates. Cells were incu-
bated with 1 µg/ml Aβ-488 and 100 nmol/l Lysotracker-Red (Thermo
Fisher Scientific, MA, USA; #L12492) and imaged using a Leica SP2
confocal microscope (Leica Microsystems, Wetzlar, Germany) for 1 hr
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with a 63x/1.4NA HCX PL APO objective. We used BV-2 cells in-
stead of primary since live imaging requires long hours and it is too
damaging for primary cultures in our laboratory conditions.
Intracellular Aβ Clearance and degradation
BV2 cells were incubated in culture medium with 1 µM soluble Aβ42
(Anaspec, Fremont, CA, USA; #As-64129) for 3 hrs in the presence
or absence of 100 ng/ml of NGF. Cells were then either collected (the
3 hrs time point) or the medium was changed after extensive washes
with PBS to ensure the removal of Aβ42 in the supernatant. After
this step, these cells were collected and lysed in ice-cold RIPA buffer
(SDS 1%) after either 5 hrs, 9 hrs or 21 hrs of washout, in order
to allow the measurement of the phagocytosed Aβ which could be
either digested (and detected in the cell extracts) or expelled (and
detected in the supernatant) at each time point - time points are not
longitudinal, they are parallel experiments. After brief sonication,
they were collected by centrifugation at 13,000 r.p.m. at 4◦C for 15
min. The supernatant at each timepoint was also collected. Aβ42
levels in the cell lysates were determined by immunoblotting with the
anti-Aβ antibody 6E10 (clone 6E10 #SIG-39320; 1:1000, Covance; NJ,
USA). The samples were resolved with 4%-15% bis-tris SDS-PAGE.
Aβ levels were measured and normalized on the housekeeping GAPDH
total protein levels. The Aβ supernatant levels were measured using
ELISA Kit (Human Aβ42 Invitrogen KHB3441). Optical density was
read at 450 nm on a Bio-Rad plate reader. BV-2 cells - as opposed
to primary microglia - were used because of the high number of cells
needed for this experiment (RRR rule).
Aβ phagocytosis in ex vivo hippocampal slices
To prepare hippocampal slices, Cx3Cr1-GFP mice were deeply anes-
thetized (20% urethane solution, 0.1 ml/100g body weight) via in-
traperitoneal injection and decapitated after tail pinch reflex disap-
pearance in order to perform the immediate dissection of brain tissue.
Horizontal slices containing the hippocampal area (200 µm thick) were
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obtained by a vibratome (Leica VT1200S). All of the above steps were
performed in ice-cold ACSF solution (artificial cerebrospinal fluid,
in mM: NaCl, 119; KCl, 2.5; CaCl2, 2; MgSO4, 1.2; NaH2PO4, 1;
NaHCO3, 26.2; glucose, 10) bubbled with 95% O2 /5% CO2. Slices
were stored in a recovery chamber containing oxygenated ACSF at
room temperature, for at least 30 min prior to the addition of 100 nM
s555-Aβ with or without 100 ng/ml of NGF. After 3 hrs, slices were
fixed in 4% PFA for 18 hrs at 4◦C. Slices were put in 30% sucrose,
then they were sectioned into 45 µm thinner slices using a Leica mi-
crotome. Brain slices were mounted on glass slides and imaged using
a 40X objective with a SP5 confocal microscope (Leica Microsystems,
Wetzlar, Germany).
Electrophysiological recordings from neurons
Adult C57BL6 male mice were deeply anesthetized with isoflurane
inhalation, decapitated, and brains removed and immersed in cold
cutting solution (4◦C) containing (in mM): 126 choline, 11 glucose, 26
NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 10 MgSO4, 0.5 CaCl2 equilibrated
with 95% O2 and 5% CO2. Coronal slices (300 µm) were cut with a
vibratome (Leica) and then incubated in oxygenated artificial cere-
brospinal fluid (ACSF) containing (in mM): 126 NaCl, 26 NaHCO3,
2.5 KCl, 1.25 NaH2PO4, 2 MgSO4, 2 CaCl2 and 10 glucose, pH 7.4;
initially at 32◦C for 1h, and subsequently at room temperature, before
being transferred to the recording chamber and maintained at 32◦C.
Recordings were obtained from visually identified pyramidal neurons
in layer 2/3, easily distinguished by the presence of an emerging api-
cal dendrite. Experiments were performed in the whole-cell configu-
ration of the patch-clamp technique. Electrodes (tip resistance = 3-4
MΩ) were filled with an intracellular solution containing (in mM): K-
gluconate 135, KCl 4, NaCl 2, HEPES 10, EGTA 4, MgATP 4 NaGTP
2; pH adjusted to 7.3 with KOH; 290 mOsm. Whole-cell voltage-
clamp recordings (-70 mV holding potential) were obtained using a
Muticlamp 700B (Axon CNS, Molecular Device). Action potential in-
CHAPTER 4. MATERIALS AND METHODS 136
dependent spontaneous excitatory postsynaptic currents (mEPSCs),
recorded in the presence of tetrodotoxin (TTX) 1 µM and the GABAA
receptor antagonist picrotoxin (100 µM), were filtered at 1 kHz, digi-
tized at 10 kHz, and recorded on computer using Digidata1440A and
pClamp10 software (Molecular Device). Series resistances were not
compensated to maintain the highest possible signal-to noise and were
monitored throughout the experiment. Recordings were discarded if
Rs changed 25% of its initial value. Spontaneous events were detected
and analyzed with Clampfit 10.4 using amplitude and area thresholds
set as a multiple (3-4X) of the SD of the noise. Each event was also
visually inspected to prevent noise disturbance of the analysis. Each
slice received only a single exposure to NGF (20 g).
Electrophysiological recordings from microglia cells
Acute cortical slices (250 µm) were obtained from CX3CR1+/GFP
male mice (P18-P30) using the identical experimental procedures de-
scribed in the above paragraph (recordings from neurons). After recov-
ering for at least 1h at RT, each slice was transferred in the recording
chamber under the microscope and perfused (2 ml/min) with warmed
ACSF (32◦C). Visually identified GFP-expressing cortical microglial
cells were patched in whole-cell configuration. Micropipettes (5-6 MΩ)
were filled with solution containing the following composition (in mM):
KCl 140, EGTA 0.5, MgCl2 2, HEPES 10, and Mg-ATP 2 (pH 7.3
adjusted with KOH, osmolarity 290 mOsm; Sigma Aldrich). Voltage-
clamp recordings were performed using a Muticlamp 700B (Axon CNS,
Molecular Device). Currents were filtered at 2 kHz, digitized (10 kHz)
and collected using Clampex 10 (Molecular Devices); the analysis was
performed offline using Clampfit 10 (Molecular Devices). Slicing pro-
cedure might activate microglial cells especially near the surface of
the slice, therefore recordings were performed on deep cells. Cells
were clamped to a holding potential of -20mV. The current/voltage
(I/V) relationship of each cell was determined applying voltage steps
from -140 to +60 mV (DVm 20mV) of 250 ms duration with interval
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of 5 seconds after whole-cell configuration was achieved (HP = -20
mV between steps). Current values for each given voltage step were
measured in the last two-thirds to avoid contamination of capacitance
artefacts. Resting membrane potential and membrane capacitance
were measured at start of recording. NGF was applied in bath for
10 minutes. One to four cells per mice were recorded. At least four
animals per group were used.
Neuron/microglia co-cultures
For neuron/microglia co-cultures, at DIV 17-19 for neurons, primary
microglia were seeded onto cultured hippocampal neurons (1x105 cells/well).
The culture was maintained in Neurobasal-A supplemented with 2%
B27, 2mM L-Glutamine and 10 ug/ml gentamicin and used after 24 hrs
for experiments. Co-cultures were treated with soluble Aβ-555 (100
nM), and 100 ng/ml NGF for 3hrs, fixed in 2% PFA and 5% sucrose
for 10 min, washed in PBS and blocked for 1 hr at room temperature
in BSA 1%. Incubation with primary antibody was performed at the
following concentrations: anti-PSD95 1:500 (Abcam Cambridge, UK;
ab9909), anti-actin 1:500 (Sigma Aldrich, MO, USA A-3853;), anti
GluA1 1:100 (Millipore, CA, USA; #AB1504;). For image acquisi-
tion, coverslips were mounted on glass slides in Fluoromount (Sigma
Aldrich, MO, USA, F4680-25ML).
Chemical LTP
Cx3Cr1-GFP microglia (2x104 cells/well) were added to DIV 17 cul-
tured hippocampal neurons. After 48hrs, the cultures were treated
with soluble Aβ-555 (100 nM), with or without 100 ng/ml NGF for
3hrs. GI-LTP was induced as reported in the literature (Ahmad et
al., 2012). Briefly, cultures were incubated for 15 min at room tem-
perature in standard ACSF (in mM : 125 NaCl, 2.5 KCl, 1 MgCl2, 2
CaCl2) with 0.02 mM Bicuculline and 0.001 mM TTX, then washed
with Mg-free ACSF and treated for 7 min with Mg-free ACSF sup-
plemented with 0.2 mM Glycine, 0.02 mM Bicuculline. After 7 min
of stimulation, cultures were washed once in ACSF and left in culture
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medium for 1h and fixed in 2% PFA for 10 min.
Measurement of inflammatory markers
Simultaneous detection of multiple cytokines was obtained using the
Mouse Inflammation Antibody Array (Raybiotech, USA, Canada; AAM-
CYT-6). Primary microglia from B6129 mice were plated in a 6-well
at the concentration of 6.5x105 cells/well in culture medium. After 18
hrs, cells were serum starved for 4 hrs, and later treated with Aβ 1 µM
or 100 ng/ml NGF or Aβ and NGF simultaneously. Cells were lysed in
ice-cold RIPA buffer (50 mM Tris/HCl, 150 mM NaCl, 1mM EDTA,
1% Igepal, 0.5% Sodium Deoxycholate, 0.1% SDS, Protease Cocktail
inhibitor) and sonicated briefly, and then collected by centrifugation
at 13,000 r.p.m. at 4◦C for 15 min. Arrays were incubated with the
appropriate blocking buffer for 2hrs. Eighty µg of protein extract were
diluted in blocking buffer and incubated with the array overnight at
4◦C. Then, arrays were washed accordingly and incubated for 3hrs at
room temperature with the Biotinylated Antibody Cocktail solution.
After washing, arrays were incubated with HRP-streptavidin for 2hrs
and detected using the Detection Buffer. Images were captured using
the Chemidoc detection system (Bio-Rad).
Image Analysis Images from AD11, VH and WT mice were ac-
quired with a confocal laser scanning microscope (TCS SP2; Leica
Microsystem, Wetzlar, Germany). 10 stacks per region per mice were
obtained. On the Z axis, images were taken every 0.4 µm. Regions of
interest for morphological changes in the microglia were the entorhi-
nal cortex and the hippocampus(specifically the molecular layer). Im-
age elaboration and analysis was conducted using Bitplane?s software
Imaris (Zurich, Switzerland). Experiments in Fig. 4.6A, 4.17: 512x512
pixel images were acquired with a confocal microscope (Leica TCS
SP2) using an oil objective: HCX PL APO 63.0X OIL (NA=1.40),
and pinhole was set to 1 AU. Sequential illumination with Ar 561 and
Ar 488 laser lines was used to detect, sAβ-555, ABOs, IBA1, TrkA,
p75 immunofluorescence. Experiments in Fig. 4.8 were acquired in
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2048x2048 pixel images with a confocal microscope (Leica SP5, Le-
ica Microsystems, Wetzlar, Germany) equipped with four laser lines:
violet diode emitting at 405 nm, argon emitting at 488 nm, and he-
lium/neon emitting at 543 and 633 nm using a HCX PL APO 40X OIL
objective, 1 zoom factor , pinhole 1 AU. Points of colocalization were
supposed when a merging area in the same cell was evident, showing
a yellow resulting color from the overlap of two green-red signals, and
they were verified by analysis on the z-axes with 1 µm-stacks. Exper-
iments in Fig.4.21A-B and 4.22: 512x512 pixel images were acquired
with a confocal microscope (Leica TCS SP5 on DM6000, equipped
with MSD module) using an oil objective HCX PL APO CS 40.0X
(NA=1.25), digital and pinhole was set to 1.5 AU. Sequential illumi-
nation with HeNe 633, DPSS 561 and Ar 488 laser lines was used to
detect Alexa647 (used for PSD95, actin and GluA1 immunofluores-
cence), sβ-555, and GFP or IBA1 immunofluorescence, respectively.
The Aβ intracellular levels was quantified by measuring the mean
555 fluorescence intensity in the area circumscribed by microglial cell
perimeter using the segmented line tool in ImageJ. Dendritic spines
were counted using ImageJ software. For this analysis, all dendritic
protrusions with a clearly recognizable stalk were counted as spines.
Spine number was divided by the length of the dendritic segment to
generate dendritic spine density, expressed as number per microme-
ter. Chemical LTP was measured by quantifying the integral GluA1
fluorescence intensity of each spine.
Data Analyses and statistics
Data are presented as means ± s.d. unless otherwise noted, using Ori-
gin (OriginLab Corporation, MA, USA). Means were compared using
the unpaired or paired t-test as indicated. Multiple comparisons were
made using one-way ANOVA test, followed by a post-hoc Bonferroni
test. The variance of each dataset was measured with an F test; ∗
p≤0.05, ∗ ∗ p≤0.01 and ∗ ∗ ∗ p≤0.001.
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